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I.   INTRODUCTION 
Today, cancer is still among the leading causes of death. In 2015 alone, an 
estimated 8.8 million people died from cancer worldwide. Thus, cancer still 
represents one of the major burdens for public health. Despite intensive 
research on new alternative treatment methods, most patients still rely on 
classical treatment options comprised of chemotherapy, radiotherapy and 
surgical intervention. 
While many strategies are being pursuit, viral immunotherapy on the basis 
of viral-vectors delivering tumor-associated antigens is on the rise. In this 
context, poxviruses serve as a promising platform for the development and 
production of therapeutic cancer vaccines. Among others, the Modified 
Vaccinia virus Ankara (MVA), a member of the Poxviridae family, is being 
investigated as a potential vector candidate. MVA has already been 
successfully tested as a vector vaccine for various infectious diseases in 
several clinical trials. It is a highly attenuated vaccinia virus strain with an 
exceptional safety profile due to its inability to productively replicate in 
human and most mammalian cells. At the same time, MVA is able to accept 
large inserts of foreign DNA and express high levels of recombinant 
proteins. In addition, MVA does not need additional adjuvant application. 
Yet, it is able to induce humoral and cellular immune responses, especially 
high levels of antigen-specific T cells, which is an important feature for use 
as a therapeutic cancer vaccine. 
The aim of this study was to investigate new approaches for enhancement 
of the efficacy of MVA as a viral vector vaccine against cancer. Therefore, 
two distinct, genetically modified recombinant MVA viruses were 
constructed and tested as candidate vaccines. These vector viruses are 
inactivated in two respectively three genes that encode for viral immune 
evasion proteins. For evaluation of vaccine immunogenicity and efficacy 
chicken ovalbumin (OVA) served as a model antigen.  
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II. LITERATURE REVIEW 
1. Immunity to tumors 
In general, cancer arises from the body’s own cells that go into abnormal 
uncontrolled proliferation resulting in a tumor, yet not every tumor classifies 
as cancer. While some tumors stay local and are classified as non-
cancerous or benign, malignant tumors are determined by their rapid 
proliferative capacity along with their ability to invade surrounding tissue and 
eventually metastasize to distant sites (HANAHAN & WEINBERG, 2011). 
Since the beginning of cancer research the possibility of cancer eradication 
by a specific immune response has always been of interest. In the 1960’s 
Frank Macfarlane Burnet firstly proposed the idea of immune surveillance 
in which he stated that the body’s immune system is not only able to detect 
and destroy invading pathogens but also cells that become cancerous 
(BURNET, 1967). Today, the existence of such a surveillance system is an 
established concept but its importance in tumor formation is still being 
controversially discussed (CORTHAY, 2014). 
1.1. Immune response to tumors  
For a long time, tumors were believed to be non-immunogenic and 
unrecognizable for the immune system. Only the investigation of 
transplantable tumors in mice led to the discovery, that immune recognition 
of tumor cells is not impossible. In the key experiments of these studies, 
mice were firstly immunized with irradiated tumor cells. Upon injection of 
viable tumor cells of the same type, no tumor development was observed. 
In contrast, mice that were injected with viable tumor cells of a different kind 
quickly developed tumors. These findings indicated for the first time, that 
tumors can express antigens that become the target of the immune system 
and were therefore described as tumor rejection antigens (JAFFEE & 
PARDOLL, 1996; MURPHY et al., 2008b). 
 
Today, it is widely accepted that tumor cells, although they are derived from 
host cells, are in fact immunogenic and elicit an adaptive immune response 
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(DISIS, 2010). Some tumors even regress spontaneously (e.g. melanomas) 
which is believed to be caused by an immunological response (PRINTZ, 
2001). The immunogenicity of tumors implies that tumor cells can express 
one or more antigens which the adaptive immune system is able to detect 
and recognize as foreign. Therefore, those tumor antigens play a key role 
in the development of cancer immunotherapy and have become a focus in 
cancer research (PARISH, 2003). 
1.2. Tumor antigens 
Our immune system has developed a sophisticated system to differentiate 
between “self” and “non-self” structures. Ideally, everything non-self-
discovered by the immune system triggers an immunological response that 
leads to elimination, while self-tolerance prevents destruction of the body’s 
own structures. Pathogens, such as bacteria, present a rich repertoire of 
proteins, lipids and carbohydrates on their cell surface, all of which are 
potential antigens for immune recognition. Thus, they are relatively easy 
detectable by immune cells. The problem that arises with cancer cells is that 
cancer derives from mutations that occur in the body’s own cells and these 
cells are protected from destruction by self-tolerance. However, these 
somatic mutations can also cause alteration of so far self-proteins presented 
of the cell surface. If those proteins were altered in a way that they can be 
detected by T-cells, they become immunogenic tumor antigens and can 
trigger an immunological response. At the same time, cancer cells 
sometimes also start to overexpress certain self-proteins, and this 
overexpression also makes them tumor-antigens that can be recognized by 
the immune system. Against this background, two types of tumor antigen 
can be differentiated: tumor-specific antigens (TSAs) caused by mutations 
and tumor-associated antigens (TAAs) caused by overexpression of self-
proteins (SRINIVASAN & WOLCHOK, 2004; SCHIETINGER et al., 2008). 
In theory, TSAs represent the ideal targets for cancer immunotherapy 
because they are highly specific, solely expressed by cancerous cells and 
often also play an important role in tumorigenicity (SCHIETINGER et al., 
2008). However, because of their high specificity they cannot be used in a 
universal approach but immunotherapeutics would have to be custom made 
for each patient or at least small subgroups of patients, which is extremely 
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time-consuming and very expensive. Therefore, TAAs have become the 
main focus in the development of cancer immunotherapies and there is an 
ongoing intensive search for ever new antigens to be used. (NELLER et al., 
2008; SCHIETINGER et al., 2008).   
 
2. Immunotherapy and cancer vaccines 
Over the last decades, intensive research on immunology and the biology 
of cancer and its development has given valuable new insights into how 
tumors develop and the way out immune systems reacts to them. Many 
studies have underlined the importance of tumor cell-specific cytolytic T-
lymphocytes (CTLs) to mediate an efficient anti-tumoral response after 
successful recognition of TAAs (KENNEDY & CELIS, 2008). That is, 
because CTLs have been proven to recognize TAAs through MHC class I 
molecules and directly kill tumor cells via lysis (GARCIA-LORA et al., 2003; 
VIGNERON, 2015). In mice, tumor specific CTLs were shown to be able to 
mediate tumor regression (ROBBINS & KAWAKAMI, 1996). Consequently, 
efforts were made to gain more knowledge on the complex mechanisms 
involved in TAA recognition and T-cell activation. These new insights were 
used in the development of a number of novel cancer treatments that focus 
on the activation of immune response and most importantly activation of 
tumor-specific CTLs. 
Among many different approaches is the broad field of cancer 
immunotherapy. Immunotherapy relies on the use of immune cells or the 
entire immune system to fight cancer cells (PARDOLL & DRAKE, 2012). 
Surprisingly, the idea of cancer immunotherapy goes back to the 19th 
century. Already in the 1890s, surgeon William Coley observed complete 
remission of cancer in a cancer patient infected with Streptococcus 
pyogenes (St. pyogenes). He then began injecting cancer patients with St. 
pyogenes (which became known as “Coley’s toxin”) and observed a cure 
rate of over 10% (COLEY, 1991; WIEMANN & STARNES, 1994). In the 
years that followed, attitude towards cancer immunotherapy kept changing 
from favor to disfavor and back again (PARISH, 2003). Today, there is little 
doubt that the immune system can detect and even eliminate tumor cells 
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and that immunotherapy is a promising concept in the field of novel cancer 
therapies. A first peak  was reached in 2013, when it was declared 
breakthrough of the year by Science magazine (COUZIN-FRANKEL, 2013).  
In general, two types of immunotherapy exist: active and passive 
immunotherapy and both approaches can either be specific or non-specific. 
While non-specific therapy only induces a general immune response, 
specific immunotherapy is able to elicit a tumor-specific immune response. 
Passive immunotherapy relies on the immunization with components of the 
immune system (e.g. monoclonal antibodies) that were created ex vivo. 
There is an immediate anti-tumoral effect, however it is only temporary and 
relies on repetitive administration. As on the other side, active 
immunotherapy activates the immune system to induce its own lasting 
response and recognize respectively attack tumor cells (SCHUSTER et al., 
2006). Recognition of tumor cells is achieved through specific TAAs 
introduced to the immune system in various ways. One way possible is the 
introduction of TAAs via therapeutic vaccines based on viral vectors.  
2.1. Vector-based delivery systems 
The general aim of every therapeutic cancer vaccine is to adequately 
generate an efficient immune response against a specific TAA. In 1994, it 
was already shown that such TAAs are recognized by both CD4+ and CD8+ 
T-cells. In addition, activated CD8+ T-cells were reported to be able to 
directly lyse TAA-presenting tumor cells (BOON et al., 1994). Out of the 
several ways of how to introduce TAAs to the immune system, the vector-
mediated presentation of TAA was shown to be highly efficient and presents 
some advantages. It was described to lead to an increase in frequency and 
avidity of TAA specific cytotoxic CD8+ T-cells (YANG et al., 2005). 
Furthermore, a vector-mediated presentation of antigens to the immune 
system was shown to be more immunogenic than when antigens were 
administered as a whole protein with adjuvant (KASS et al., 1999). Taken 
together it becomes clear that viral-vector based delivery platforms have a 
high potential in the development of therapeutic cancer vaccines. In this 
context, poxviruses have emerged as promising candidates for the 
development of safe and efficacious vaccines for both infectious diseases 
and cancer (SANCHEZ-SAMPEDRO et al., 2015). 
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Although there are many different viral vectors being investigated which are 
very diverse, one important feature of all of them is their replication 
competence in humans. Vectors that cannot only infect cells but are also 
able to replicate and spread are being investigated for use in oncolytic 
virotherapy. The term oncolytic refers to the property of these viruses to 
selectively replicate in cancer cells and by doing so, killing them through 
lysis and spreading to uninfected tumor cells (FUKUHARA et al., 2016) 
At the same time, lysis not only actively destroys tumor cells but also triggers 
an immune response against the tumor, likely due to the release of tumor 
antigens (LAROCCA & SCHLOM, 2011). In addition, they are mostly 
engineered to also express one or more TAAs to elicit an additional anti- 
tumoral immune response. That way, oncolytic viruses are able to fight 
cancer cells at two fronts. In this context, Vaccinia virus (VACV) has 
emerged as a promising oncolytic agent that is being engineered to express 
various TAAs and has entered numerous clinical trials (RUSSELL et al., 
2012). However, the replication capacity of oncolytic vectors is advantage 
and disadvantage at the same time. While healthy individuals usually show 
good responses and tolerate the vector quite well, immunosuppressed 
people are at great risk to experience serious adverse effects, even with 
fatal outcome, due to replication of the vector beyond control (KELLY & 
RUSSELL, 2007). That is of course of major concern in cancer patients, 
especially when oncolytic viruses are used as follow-up treatment after 
radiation and/or chemotherapy. Because of that, more and more replication 
deficient viruses are being investigated as therapeutic cancer vaccines. 
They can be engineered to express TAAs and elicit a strong anti-tumor 
immune response, but due their replication deficient phenotype, they can 
safely be administered to immunocompromised people and can serve as a 
save alternative to replicating oncolytic viruses. In this context, Modified 
Vaccinia virus Ankara has evolved as a promising candidate for the 
development of TAA expressing therapeutic cancer vaccines (KREIJTZ et 
al., 2013).    
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3. Modified Vaccinia virus Ankara 
3.1. MVA: a member of the Poxvirus family 
Modified Vaccinia virus Ankara (MVA) is a highly attenuated strain of VACV, 
a member of the family Poxviridae. The family is divided into two 
subfamilies, the vertebrae specific Chordopoxvirinae and insect specific 
Entomopoxvirinae. The Chordopoxvirinae subfamily is further divided into 
nine genera, one of them being the genus Orthopoxvirus. VACV is the 
prototype member of the genus Orthopoxvirus along with one of its most 
famous members, variola virus, the causative agent of smallpox.  
Poxviruses are exceptionally large enveloped viruses with brick-shaped 
geometry (ca. 250 nm x 360 nm). They contain a large (130-300 kilobase 
pais) s-shaped genome of double stranded DNA (dsDNA) with single 
stranded terminal hairpin loops (MOSS et al., 1996). The central region of 
the genome is highly conserved among poxviruses and mostly consists of 
open reading frames (ORFs) associated with replication while the terminal 
regions are more diverse and dedicated to host range and immune evasion 
(MOSS, 2007; WERDEN et al., 2008). Poxviruses present two distinct forms 
of infectious particles: a mature virion (MV) and an extracellular enveloped 
virion (EV). Their structure is very similar with a dsDNA containing Core, 
two lateral bodies and an outer membrane. The EV additionally possesses 
another outer protein containing lipid membrane, the EV envelope (MOSS, 
2007) (Fig. 1). While MVs represent the more frequent particle, EVs are 
essential for an efficient cell-to-cell and long-range spread (BLASCO & 
MOSS, 1992).  
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Fig. 1: Poxvirus morphology 
(Source: ViralZone; www.expasy.org/viralzone; SIB Swiss Institute of 
Bioinformatics, with permission) 
 
3.2. Poxviruses as viral vectors  
Despite the fact that many poxviruses are the cause of serious disease, 
some even with zoonotic potential (BAXBY, 1988) they also have a long 
history in the development of potent vaccines (SANCHEZ-SAMPEDRO et 
al., 2015). Most famously, VACV was used as the active component of the 
smallpox vaccine that was used in the worldwide smallpox eradication 
program with over one billion people vaccinated. The program was declared 
a success in 1979, which made smallpox the first infectious disease to have 
ever been eradicated (FENNER et al., 1988). Post-eradication, the study of 
VACV was perpetuated and focused on the use of VACV for gene 
expression and viral vector based vaccines (MACKETT et al., 1982; 
PANICALI & PAOLETTI, 1982). Especially in terms of vector-based vaccine 
development, poxviruses in general promise many advantages. They have 
been proven to make stable recombinants along with successful processing 
of foreign proteins (SUTTER & MOSS, 1992). Furthermore, due to their own 
large genome, they are not only capable of accepting large inserts of foreign 
DNA (SMITH & MOSS, 1983) but can even accommodate multiple genes 
at once, which enables them to express more than one antigen (PERKUS 
et al., 1985). Furthermore, it was shown, that the expressed antigen is 
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processed and then presented by both major histocompatibility complex 
(MHC) class I and II molecules, thus activating both CD4+ and CD8+ T-
lymphocytes (TSANG et al., 1995). In addition, an antigen-specific humoral 
response has also been described along with the induction of protective 
immunity in mice (SUTTER et al., 1994). Regarding the safety profile of 
poxviruses it is of advantage, that their replication is limited to the cell’s 
cytoplasm, thus no risk of insertional mutagenesis exists (ROBERTS & 
SMITH, 2008). Furthermore, poxviruses do not persist in the host after 
infection. However, some side effects have also been observed, partly 
severe, after VACV inoculation, mostly attributed to its replicative capacity. 
Particularly, immunocompromised people were at risk, which led to the 
search for safer poxvirus alternatives. The search came to an end with the 
discovery of second-generation VACV derived vectors, such as replication 
deficient MVA (SUTTER & MOSS, 1992).  
3.3. MVA as an expression vector 
MVA was derived from Chorioallantois Vaccinia virus Ankara (CVA) after 
CVA was passaged more than 500 times in primary chicken embryo 
fibroblasts (CEF) in an attempt to generate a VACV with reduced virulence 
(MAYR & MUNZ, 1964; MAYR et al., 1975). During passaging, MVA lost 
about 15% of genomic information compared to CVA, including six major 
deletion sites and numerous other small deletions, most of which affect 
virulence and immune evasion, drastically reducing pathogenicity (MEYER 
et al., 1991; ANTOINE et al., 1998). As a result, MVA was found to be no 
longer able to replicate in human and most other mammalian cells but its 
propagation was limited to avian cells, making it an exceptionally safe 
vaccine candiate (MEYER et al., 1991; DREXLER et al., 1998). MVA’s 
safety profile was confirmed after more than 100,000 individuals in Bavaria 
received MVA as a smallpox vaccine and only little side effects were 
observed (STICKL et al., 1974; MAYR et al., 1978). Moreover, MVA has 
also been extensively studied as an expression vector for the construction 
of vaccines against different infectious dieseases and cancer (SUTTER & 
STAIB, 2003; KREIJTZ et al., 2013; VOLZ & SUTTER, 2017). Although 
MVA lacks replicative capacity, it can still infect mammalian cells with no 
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negative effect on early, intermediate and late gene expression, making way 
for the successful expression of foreign antigens (SUTTER & MOSS, 1992). 
Remarkably, when comparing replication competent VACV to MVA 
expressing the same antigen in terms of immunogenicity and protective 
capacity, MVA was shown to be equally effective if not slightly better 
(SUTTER et al., 1994; CARROLL et al., 1997). Concerning immunogenicity, 
many studies have proven MVA’s capacity to potently stimulate innate 
immunity, including the induction of IL-1β (WAIBLER et al., 2007; 
DELALOYE et al., 2009; LEHMANN et al., 2009). Furthermore it was 
shown, that no adjuvants are required in an MVA based vaccine compared 
to non-vector based vaccines, adding to its good safety profile (KREIJTZ et 
al., 2013). To further assess safety, MVA was tested in immunosupressed 
monkeys and no severe side effects were observed, confirming once again  
that MVA in contrast to VACV can be administered to immunocompromised 
people (STITTELAAR et al., 2001).  
One concern often expressed for the use of viral vectors is the induction of 
neutralizing antibodies against the vector itself, limiting their use to a one-
time-only application. Despite MVA-neutralizing antibodies being detectable 
after immunization, several studies have shown that strong antigen-specific 
immune responses can be boosted repeatedly upon multiple 
administrations of recombinant MVA (HARROP et al., 2010; GOEPFERT et 
al., 2011; KREIJTZ et al., 2014).  Thus, MVA was found to be an efficacious, 
immunogenic alternative to VACV that holds many advantages and 
presents a very high safety profile for clinical use.  
Today, MVA is a well studied viral vector in both preclinical and clinical 
research.  Many recombinant MVAs have been developed as vaccine 
candidates against different infectious diseases, e.g. influenza, west nile, 
HIV and also bacterial and intracellular pathogens like malaria and 
tuberculosis. In more recent years, MVA has also become increasingly 
interesting for the construction of various therapeutic cancer vaccines with 
many of these candidates having already entered clinical trials. (GILBERT, 
2013; KREIJTZ et al., 2013; ALTENBURG et al., 2014; GOEPFERT et al., 
2014; KREIJTZ et al., 2014; SHEEHAN et al., 2015; SEBASTIAN & 
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GILBERT, 2016; VOLZ & SUTTER, 2017). 
3.4. Immunomodulation by MVA 
In theory, virus infection of a cell is detected by pattern recognition receptors 
(PRRs) and leads to an immune response, which interrupts replication, 
stops spreading and eventually clears the infection while possibly inducing 
immunity. In response, most viruses, including poxviruses, have evolved 
many strategies to either avoid detection or directly interfere with the host’s 
immune response (i.e. immunomodulation) (MURPHY et al., 2008b). For 
example, such immunomodulatory strategies interrupt signaling pathways 
that would lead to cell death, production of interferons (IFNs), cytokines and 
chemokines as well as the activation of cytotoxic T-lymphocytes (CTLs) and 
natural killer cells (NKs) (SEET et al., 2003; HAGA & BOWIE, 2005). As a 
result of extensive studies conducted on virus-host-interaction in VACV as 
a prototype poxvirus, many immunomodulatory genes have been identified 
and described over the years and it is estimated that VACV dedicates about 
one half of its genome to encode virulence, host-range and 
immunomodulatory proteins (SMITH et al., 2013). In general, 
immunomodulatory proteins found in poxviruses can be subdivided into 
three different functional classes: virostealth, viromimicry and 
virotransduction. Virostealth describes the ability to block the presentation 
of antigen to immune cells, thus down regulating antigen recognition. 
Viromimicry means the production of viral proteins that mimic cytokines, 
chemokines or their receptors and virotransduction is the inhibition of innate 
antiviral responses such as the induction of apoptosis in infected cells 
(JOHNSTON & MCFADDEN, 2003). 
However, the majority of immunomodulators known in VACV were depleted 
in MVA during passaging in CEF cells. Nevertheless, few 
immunomodulators are still present in MVA, some of which have been 
identified, studied and were shown to influence both, the innate as well as 
the acquired immune response (GARCIA-ARRIAZA & ESTEBAN, 2014). 
The study of MVA and its interaction with the host’s immune response is an 
especially important aspect when it comes to the use of MVA as a viral 
vector for therapeutic cancer vaccines. That is because immunomodulators 
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interfere with the fundamental principle of any given vaccine:  to provoke an 
adequate and strong immune response. Therefore, depletion of certain 
immunomodulatory genes in MVA can be an attractive approach to further 
enhance MVA’s immunotherapeutic effects and strengthen its capacity to 
induce strong immunity against the desired antigen(s).  
3.4.1. Interleukin-1β 
Interleukin 1β (IL-1β) is a well-known member of the interleukin-1-
superfamily. Originally only comprised of IL-1α and IL-1β, today the family 
includes a total of 11 cytokines. Stronger than any other cytokine family, the 
IL-1 family is primarily linked to inflammation, both acute and chronic. Most 
of its members including IL-1β show strong pro-inflammatory properties 
while only one (IL-37) is known to be anti-inflammatory (DINARELLO, 
2011). Structurally, IL-1β is a monomer, consists of 153AA and is primarily 
produced by activated macrophages (MURPHY et al., 2008a). It is 
synthesized in form of an inactive 31kDa proenzyme and activation occurs 
upon cleavage of pro-IL-1β into mature 18kDa IL-1β by activated Caspase-
1 (formerly known as the Interleukin-1 converting enzyme, ICE) in response 
to various danger signals (DINARELLO, 2009; LOPEZ-CASTEJON & 
BROUGH, 2011). IL-1β is known to activate T-cells, the vascular 
endothelium and to lead to local tissue destruction at the side of release. 
Systemically, it is a very potent endogenous pyrogen inducing fever and the 
major pyrogen in a poxvirus infection (ALCAMI & SMITH, 1996). In addition, 
IL-1β activates hepatocytes to synthesize and release acute-phase 
proteins, which then act as opsonins (MURPHY et al., 2008c). In contrast to 
VACV, IL-1β is one of the pro-inflammatory cytokines that was shown to be 
induced during MVA infection (DELALOYE et al., 2009).  
Il-1β and IL-1α both share the same receptors which belong to the IL-1 
receptor (IL-1R) superfamily: The Type I IL-1 receptor (IL-1RI, CD121a) and 
the Type II IL-1 receptor (IL-1RII, CD121b), both of which are able to bind 
mature IL-1β. To initiate a signal, recruitment of a coreceptor is required, 
the IL-1 receptor accessory protein (IL-1RAcP). However, only binding to 
the IL-1RI can activate a signal transduction (Fig. 2a) since IL-1RII lacks the 
needed cytoplasmatic domain, thus serves as a decoy receptor to regulate 
levels of IL-1β (Fig. 2b). Besides the occurrence of a decoy receptor, a 
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receptor antagonist additionally exists for the regulation of IL-1β secretion: 
the Interleukin-1 receptor antagonist (IL-1Ra) is able to bind to IL-1RI and 
by doing so blocking it for IL-1β (DINARELLO, 2009).  
As shown in figure 2a, mature IL-1β first binds to the IL-1RI which is followed 
by the recruitment of IL-1RAcP, forming a heterodimeric complex. The 
signal is then initiated through the recruitment of the adaptor protein MyD88 
by the two Toll-IL-1 receptor (TIR) domains of both receptors. This leads to 
phosphorylation of IRAKs followed by IKKβ, eventually resulting in the 
translocation of NF-ĸB into the nucleus and initiation of pro-inflammatory 
signals. At the same time, recruitment of MyD88 also stimulates the 
transcription and translation of IL-1β-mRNA in a way that mature IL-1β up 
regulates itself (DINARELLO, 2009). In addition to activation by Caspase-
1, non-caspase dependent mechanisms have also been identified that are 
able to generate active IL-1β (FANTUZZI et al., 1997). 
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Fig. 2: IL-1β pathway. (A) Only binding to IL-1RI can initiate a signal that 
leads to pro-inflammatory stimuli and up regulation of IL-1β. (B) IL-1RII is 
missing a cytosolic TIR domain and serves as a decoy receptor. 
 
3.4.2. MVA’s IL-1β receptor homolog  
One of the immunomodulatory proteins still conserved in MVA is the viral 
IL-1β receptor (vIL-1βR) homolog, which is encoded by the 927bp open 
reading frame (ORF) 184R. The secreted soluble protein is 326AA in length 
(MEISINGER-HENSCHEL et al., 2007) and was shown to be expressed late 
during the life cycle, which is consistent with the viral IL-1βR homolog 
described in VACV (ZIMMERLING et al., 2013). Furthermore, it was also 
shown to be highly specific for binding mature IL-1β whereas it is unable to 
bind Interleukin-1α (ALCAMI & SMITH, 1992; BLANCHARD et al., 1998). 
Thus, MVA’s vIL-1βR mimics the host cell’s own IL-1RI and is an example 
of viromimicry as described before (JOHNSTON & MCFADDEN, 2003).  
In 1996, the vIL-1βR was published as the first example of how viruses are 
able to inhibit fever to promote virus survival (ALCAMI & SMITH, 1996).  
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While the deletion of the homolog B15R ORF in VACV was demonstrated 
to clearly enhance severity of illness and overall pathogenicity in mice 
(ALCAMI & SMITH, 1992), it was reported for MVA that its avirulent 
phenotype remained intact. However, depletion of the gene in MVA was 
shown to lead to an enhanced memory CD8+ T-cell response in mice 
towards the inserted antigens, resulting in a better protection against a lethal 
challenge (STAIB et al., 2005; ZIMMERLING et al., 2013).  
3.4.3. Interleukin-18 
Interleukin 18 (IL-18) is a pro-inflammatory cytokine produced by activated 
macrophages and dendritic cells and was originally identified in 1989 as the 
“IFN-γ inducing factor” (NAKAMURA et al., 1989; OKAMURA et al., 1995; 
WAWROCKI et al., 2016). It is produced as a precursor protein and is 
structurally related to the IL-1 family, which is resembled by the fact that 
premature IL-18 is also activated by caspase-1 (GU et al., 1997). In addition, 
the IL-18 receptor (IL-18R) shares sequence homology to the IL-1R 
superfamily (BORN et al., 1998; THOMASSEN et al., 1998). Therefore, it is 
currently considered a full member of the IL-1 superfamily. In contrast to IL-
1β, the IL-18 precursor protein is continuously expressed in several cells 
including epithelial cells throughout the gastrointestinal tract (DINARELLO 
et al., 2013). Concerning its function, IL-18 plays an important role in the 
regulation of both the innate and adaptive immune response. It stimulates 
IFN-γ production in natural killer cells (NKs) and T-cells. Furthermore, it 
promotes NK cell cytotoxicity and stimulates T-cell proliferation (BORN et 
al., 2000; READING & SMITH, 2003). IL-18 also acts synergistically with IL-
12 and together they promote a CD4+ T-cell response (Th1), increasing IFN-
γ production and cell-mediated immunity, defending the cell against 
intracellular microbes (READING & SMITH, 2003; MURPHY et al., 2008c). 
The antiviral effect of IL-18 in poxvirus infections was shown when in mice, 
which were intravenously inoculated with VACV, development of poxvirus 
legions was suppressed by treatment with IL-18 (TANAKA-KATAOKA et al., 
1999).  
IL-18 binding proteins (IL-18bps) exist and have been described in both 
humans and mice. Although they share no significant homology to neither 
subunit of the IL-18R, they can bind and neutralize mature IL-18 and 
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supposedly play an important regulatory role and can modulate the Th1 
response (NOVICK et al., 1999).   
 
 
Fig. 3: IL-18 signal transduction. Mature IL-18, IL-18Rα and IL-18Rβ form 
a high affinity complex, leading to the approximation of both receptor TIR 
domains followed by recruitment of MyD88, phosphorylation of the four 
IRAKs and TRAF-6, degradation of IKKβ and release of NFĸB. (modified 
according to (DINARELLO & FANTUZZI, 2003), with permission). 
 
The IL-18R is composed of two subunits, the IL-18Rα chain and the IL-18Rβ 
chain. The α chain is considered the ligand binding chain for mature IL-18 
while the β chain is considered a co-receptor needed for a full signal 
transduction similar to IL-1RAcP. Thus, only cells expressing both chains 
are able to signal. Firstly, mature IL-18 forms a complex of low affinity with 
IL-18Rα. Only after additional recruitment of IL-18Rβ, a high affinity complex 
in form of a heterodimer is formed, followed by an approximation of two TIR 
domains. What follows is a cascade of recruitment of MyD88, 
phosphorylation of the four IRAKs and TRAF-6, degradation of IKKβ and 
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finally the release of NFĸB as a broad proinflammatory stimulus (Fig.3) 
(WAWROCKI et al., 2016). In contrast to IL-1, where very low 
concentrations are sufficient to trigger a signal, IL-18 requires much higher 
levels (LEE et al., 2004).     
3.4.4. MVA’s viral IL-18 binding protein 
Another VACV immunoregulatory protein that is still conserved in MVA is 
the viral IL-18 binding protein (vIL-18bp). It is encoded by the 008L ORF 
(C12L in VACV), which is 360 bp in length (MEISINGER-HENSCHEL et al., 
2007). The mature protein is approximately 13kDa in VACV and is secreted 
as a soluble protein from infected cells that is able to bind mature IL-18 
(BORN et al., 2000; SYMONS et al., 2002). The vIL-18pb is widely 
distributed among orthopoxviruses and other poxvirus genera and its amino 
acid sequence was shown to be highly homologous to IL-18 binding proteins 
found in humans and mice (NOVICK et al., 1999; SYMONS et al., 2002). 
Several deletion mutants have been constructed and tested concerning 
virulence and immunogenicity. Deletion of the C12L gene from VACV strain 
Western Reserve (WR) led to virus attenuation (SYMONS et al., 2002). 
Deletion of the corresponding ORF in ectromelia virus was associated with 
higher levels of IFN-γ and increased cytotoxic activity of NK cells (BORN et 
al., 2000).Deletion of the vIL-18bp from MVA was shown to improve the 
vector immunogenicity by increasing magnitude and quality of the specific 
cellular response (FALIVENE et al., 2012).  
3.4.5. Cell death and immunity 
Regulated cell death is a physiological property of all somatic cells and 
occurs in response to a change in either intra- or extracellular environment 
(ELMORE, 2007). It is a highly regulated and finely controlled mechanism 
to remove damaged or infected cells and considered a powerful anti-viral 
tool (HENGARTNER, 2000). One reason for that is that cell death inevitably 
leads to the complete shut-down of the cell including the entire intracellular 
machinery. Viruses however rely on a functional intracellular environment 
to productively replicate before spreading to other cells or tissues and 
continue the chain of infection (COLLINS, 1995; RAZVI & WELSH, 1995). 
Hence, cell death interrupts the virus replicative cycle and if it occurs early 
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enough during infection, it will stop further spreading (HAGA & BOWIE, 
2005). Furthermore, regulated cell death can potentially alert neighboring 
cells to the threat of infection via the release of immunostimulatory 
molecules (TAYLOR et al., 2008). Thus, it is of no surprise that many 
viruses, including poxviruses, encode different anti-apoptotic proteins to 
cope with this defense strategy, preserve cell viability and prolong virus 
survival (ROULSTON et al., 1999; TAYLOR & BARRY, 2006; GALLUZZI et 
al., 2008). Cells on the other hand present a rich repertoire of different types 
of cell death and versatile signaling ways to induce them. In principle, three 
different types of cell death can be differentiated, i.e. apoptosis, pyroptosis 
and necroptosis (JORGENSEN et al., 2017). 
3.4.5.1. Apoptosis 
Apoptosis, or programmed cell death, is characterized by the disassembly 
of the cell from within while the plasma membrane remains intact. One 
distinct event of apoptotic cell death is karyorrhexis, i.e. the destructive 
fragmentation of the cell’s nucleus, which leads to irregular distribution of 
chromatin throughout the cytoplasm (ZAMZAMI & KROEMER, 1999).  But 
because the plasma membrane remains intact, no intracellular components 
potentially harmful to neighboring cells and surrounding tissue are released 
(TAYLOR et al., 2008). What is left is so called apoptotic bodies, which are 
eliminated via phagocytosis by dendritic cells (DC’s) (GREINER et al., 
2006). Once the DC’s pick-up the apoptotic bodies, they are processed and 
foreign antigens are presented to T- lymphocytes via MHC class I 
molecules, enhancing the immune response. This process is known as 
cross-presentation and allows for apoptosis to be of immunogenic 
importance via the activation of CD8+ cytotoxic T- lymphocytes (CTLs) 
(ALBERT et al., 1998). Furthermore, it was also shown that cells undergoing 
apoptosis send signals, which induce the migration of phagocytes (LAUBER 
et al., 2003).  
Apoptosis and its initiation are highly regulated by the cell, primarily because 
once activated, apoptosis cannot be stopped and inevitably leads to cell 
death (BOHM & SCHILD, 2003). In principle, it can be triggered by two 
different pathways, the intrinsic or mitochondrial pathway and the extrinsic 
pathway, both of which culminate in the activation of terminal caspases (i.e. 
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caspase 3 and 7), which activate nucleases and lead to apoptosis 
(GALLUZZI et al., 2008) (Fig. 4). 
 
The extrinsic pathway 
The extrinsic pathway is a death-receptor mediated cascade triggered by 
death ligands such as Fas ligand (FAS) and tumor necrosis factor α (TNFα) 
that bind to the tumor necrosis factor receptor (TNFR) on the cell surface. 
Upon binding, oligomerization of ligand and receptor occurs and induces 
the intracellular assembly of the so-called death-inducing signaling complex 
(DISC). This complex is essential to create yet another complex, the 
ripoptosome (complex IIa), consisting of receptor interacting protein kinase 
1 (RIPK1), Fas associated via death domain (FADD) and pro-caspase-8 
(TENEV et al., 2011). The ripoptosome activates caspase 8 through 
cleavage of pro-caspase-8. Mature Caspase-8 is then biologically active 
and activates the terminal caspases (i.e. caspase-3, -6 and -7) and 
nucleases, finally causing apoptosis (Fig. 4) (GALLUZZI et al., 2008). 
 
The intrinsic pathway 
The intrinsic pathway on the other hand is controlled by the mitochondrium, 
which serves as a control unit for incoming competing pro-apoptotic and 
anti-apoptotic signals. Apoptosis is initiated once the pro-apoptotic proteins 
overcome the anti-apoptotic proteins. Both groups belong to the B-cell 
lymphoma 2 family (Bcl-2) that includes Bcl-2 and Bcl-2-like proteins. While 
anti-apoptotic proteins share similarity in four Bcl-2-homology (BH) 
domains, pro-apoptotic proteins only share homology to the third domain 
(BH3) (WILLIS & ADAMS, 2005; CHIPUK et al., 2010). Anti-apoptotic 
proteins prevent cell death by maintaining mitochondrial integrity through 
the inhibition of effectors Bax and Bak (CORY & ADAMS, 2002; YOULE & 
STRASSER, 2008). In contrast, pro-apoptotic proteins such as Bid and Bim 
are able to activate Bax and Bak (REN et al., 2010). Upon activation, Bax 
and Bak oligomerize and form pores in the mitochondrial membrane, 
referred to as mitochondrial membrane permeabilization (MMP) 
(KORSMEYER et al., 2000; DEGLI ESPOSTI & DIVE, 2003). MMP leads to 
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the release of the apoptogenic molecule cytochrome c into the cytosol 
(HENGARTNER, 2000). Once inside the cytosol, cytochrome c enables the 
assembly of the so called apoptosome complex, consisting of pro-caspase-
9 and the apoptosis protease-activating factor 1 (APAF-1). The apoptosome 
activates caspase-9, which then again activates terminal caspases and 
causes apoptosis. At the same time, the intrinsic pathway can additionally 
be activated by the extrinsic pathway, because mature caspase 8 can not 
only activate terminal caspases but also the pro-apoptotic BH3-only protein 
Bid (Fig. 4) (SHIMIZU et al., 1999; GALLUZZI et al., 2006; GALLUZZI et al., 
2008). 
 
3.4.5.2. Pyroptosis 
Pyroptosis is a more recently described form of cell death and unlike 
apoptosis it is characterized by lysis of the cell and the release of 
intracellular pro-inflammatory content (COOKSON & BRENNAN, 2001). 
Like apoptosis, it is caspase dependent but it is solely induced by caspase-
1 (MIAO et al., 2011). Thus, caspase-1 deficient cells are unable to perform 
pyroptosis and usually undergo apoptosis when triggered (FINK & 
COOKSON, 2005). Caspase-1 can proteolytically activate caspase 7, one 
of the terminal caspases of apoptosis, showing  a cross link between 
apoptosis and pyroptosis (MIAO et al., 2011).  
Caspase-1 is present in the cytosol of phagocytic cells in form of an inactive 
proenzyme termed pro-Caspase-1. Stimulation by various danger signals 
leads to the formation of the inflammasome, a multi protein complex 
consisting of an adaptor molecule (ASC), a cytosolic PRR (e.g. NLR) and 
pro-Caspase-1. Formation of the inflammasome facilitates cleavage of pro-
Caspase-1 and subsequent release of active Caspase-1 (FRANCHI et al., 
2009; SCHRODER & TSCHOPP, 2010). Caspase-1 is considered a highly 
pro-inflammatory caspase because it proteolytically cleaves the precursor 
proteins of pro-inflammatory cytokines IL-1β and IL-18 into active proteins 
(FANTUZZI & DINARELLO, 1999). However, recent data has shown that 
Caspase-1 also cleaves the gasdermin D (GSDMD) protein. GSDMD 
cleavage then results in an N-terminal product, GSDMD-NT, which was 
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proven to trigger pyroptosis (HE et al., 2015; LIU et al., 2016). It mediates 
the formation of plasma-membrane pores, allowing influx of water into the 
cell that leads to swelling, membrane rupture and lysis, explaining the 
distinct morphological differences of pyroptosis and apoptosis (LIU et al., 
2016).  
  
Fig. 4: The intrinsic and extrinsic pathways of apoptosis. While the 
intrinsic pathway is orchestrated by the mitochondrium, the extrinsic 
pathway is a death-receptor mediated cascade (YOULE & STRASSER, 
2008, with permission). 
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3.4.5.3. Necroptosis 
Necroptosis, also referred to as programmed necrosis, is yet another form 
of programmed cell death. Like the extrinsic apoptotic pathway, necroptosis 
is triggered by TNF. The difference between both ways is that necroptosis 
is caspase-8 independent (VERCAMMEN et al., 1998). Thus, it occurs 
when the extrinsic pathway of apoptosis is triggered but caspase-8 activity 
is compromised (CHAN et al., 2015). In this case, the ripoptosome (complex 
IIa) is formed but is either lacking caspase-8 completely or contains an 
inactive form of caspase-8 (e.g. due to caspase-8 inactivating infectious 
agents or certain pharmaceuticals). This leads to the stabilization of 
receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 
and the conversion of the ripoptosome into the necrosome (complex IIb) 
(CHAN et al., 2015). This new complex activates mixed lineage kinase 
domain-like (MLKL), which is phosphorylated, oligomerized and eventually 
translocated into the cell membrane, where it causes membrane leakage 
and the release of damage-associated molecular patterns (DAMPs) (SUN 
et al., 2012; CAI et al., 2014; SUN & WANG, 2014; CHAN et al., 2015). 
3.4.6. MVA’s F1 protein 
Another immunomodulatory protein still conserved in MVA is the F1 protein, 
encoded by the F1L ORF. The mature protein is 26 kDa in size and was 
shown to be expressed early during the viral life cycle (POSTIGO et al., 
2006). It has been identified as a viral Bcl-2 homologous protein in VACV 
that inhibits the mitochondrial apoptotic pathway (WASILENKO et al., 2003). 
Although homology between F1 and Bcl-2 is rare with no obvious sequence 
semblance, F1 was shown to possess a C-terminal transmembrane domain, 
which serves as an anchor and enables mitochondrial localization 
necessary for anti-apoptotic activity (WASILENKO et al., 2003; STEWART 
et al., 2005; CAMPBELL et al., 2010). 
The anti-apoptotic activity is exerted by F1 through the prevention of release 
of cytochrome c into the cytosol. F1 was shown to directly interact with Bak 
as well as the BH3 domain of Bim. By binding to Bak, F1 prevents 
oligomerization of Bak with activated Bax, disabling pore formation 
(WASILENKO et al., 2005; POSTIGO et al., 2006; CAMPBELL et al., 2010). 
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At the same time activation of Bax is also restricted by inhibition of Bim 
(TAYLOR et al., 2006) by F1 with the same effect. Additionally, F1 was also 
shown to bind to and inhibit already activated caspase-9. Accountable for 
this is the N-terminal region of the F1 protein (ZHAI et al., 2010). Thus, the 
F1 protein enables VACV to interrupt the intrinsic apoptotic pathway of 
infected cells in two sequential steps (WASILENKO et al., 2001; ZHAI et al., 
2010) (Fig. 5) 
Besides inhibition of the mitochondrial pathway of apoptosis, F1 has 
recently been reported to also interfere with pyroptosis. It was shown to 
inhibit the formation of the inflammasomes by targeting proteins of the 
nucleotide-binding domain, leucine-rich repeat and pyrin domain containing 
protein (NLRP) family. Inhibition of the inflammsomes prevents activation of 
caspase-1, hindering gasdermin D cleavage and thus preventing pyroptosis 
(GERLIC et al., 2013). At the same time, prevention of caspase-1 activation 
also reduces levels of pro-inflammatory cytokines IL-18 and IL-1β which 
need caspase-1 cleavage for activation (Fig. 5). 
For MVA, it was shown that expression of F1 prohibited cells from 
undergoing apoptosis. At the same, absence of the F1L ORF in MVA led to 
apoptosis induction and that this induction relies on Bak and Bax (FISCHER 
et al., 2006). Furthermore, deletion of the F1L ORF was reported to not only 
induce apoptosis in vitro but enhance antigen-specific immunogenicity in 
vivo, with significantly higher antigen-specific CD8+ T cell responses 
(PERDIGUERO et al., 2012a; HOLGADO et al., 2016).  
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Fig. 5: Inhibition of cell death by MVA’s F1protein. 
  
3.5. MVA as a therapeutic cancer vaccine 
Several recombinant MVAs have been constructed as immunotherapeutic 
vaccines, some of which have entered clinical trials for different types of 
cancer. One promising candidate is TG4010, a recombinant MVA 
expressing mucin-1 (MUC1) as a TAA along with human interleukin-2 (IL-
2). Previous studies have suggested, that in addition to expressing TAAs, 
the expression of cytokines such as IL-2 can enhance the vaccines efficacy 
by increasing T-cell avidity (KUDO-SAITO et al., 2007b; KUDO-SAITO et 
al., 2007a). TG4010 has entered numerous phase II clinical studies for 
various types of cancer (e.g. prostate cancer, renal cell carcinoma) as single 
and combination treatment and has recently entered a phase IIB/III trial for 
non-small-cell lung cancer (NSCLC) (RAMLAU et al., 2008; DREICER et 
al., 2009; OUDARD et al., 2011; QUOIX et al., 2011; QUOIX et al., 2016). 
A second MVA-based candidate vaccine is OXB-301, commercially referred 
to as TroVax®. It consists of MVA delivering 5T4 as a TAA, which is a human 
oncofetal glycoprotein rarely detected in normal tissue but highly expressed 
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in many carcinomas (SOUTHALL et al., 1990). TroVax® is currently being 
developed and tested by Oxford BioMedica. It has undergone multiple 
phase II clinical studies and one phase III study with promising results 
(HARROP et al., 2006; HARROP et al., 2007; AMATO et al., 2008b; AMATO 
et al., 2008a; ELKORD et al., 2008; HARROP et al., 2008; AMATO et al., 
2009; KAUFMAN et al., 2009; AMATO et al., 2010; HARROP et al., 2013). 
Fortunately, all these clinical studies showed that all the recombinant MVAs 
were always immunogenic, well tolerated and safe with only little adverse 
effects. However, none of the MVAs were successful as monotherapies. 
Nevertheless, when administered as combinational therapy along with the 
standard of care for the specific cancer types, clinical outcome was 
generally improved. Especially a combinational approach of therapeutic 
cancer vaccines with conventional cytotoxic chemotherapy seems 
promising. While chemotherapy can be used to debulk the tumor mass, 
follow-up treatment with a vaccine induces immunity, which can be used to 
control micrometastatic disease (DRAKE, 2012). Thus, improving MVA as 
a vector itself by increasing its potential to elicit a stronger immune response 
can be used in an approach to further improve MVA-based cancer 
immunotherapy. 
 
4. Ovalbumin as a model antigen 
The use of model antigens to investigate genetically modified MVAs in terms 
of immunogenicity is a well-established concept. There are several model 
antigens that are commonly used for that purpose, such as green 
fluorescent protein (GFP), β-Galactosidase and ovalbumin (OVA). 
Particularly OVA is a well characterized model antigen has been used in 
many studies with modified MVAs to evaluate the strength of the immune 
response, especially to assess T-cell responses (BAUR et al., 2010; 
BECKER et al., 2014). OVA is a chicken egg white protein and was 
classified as a member of the serpin superfamily when it was first discovered 
(HUNT & DAYHOFF, 1980). Originally, members of the serpin family were 
all considered serine protease inhibitors. However, OVA was later shown to 
lack protease inhibitory activity, yet remained part of the family and is now 
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a member of a sub-group known as ovalbumin-related serpins (ov-serpins). 
Although its main function is still unknown, it is believed to be a storage 
protein (BENARAFA & REMOLD-O'DONNELL, 2005). Today, OVA is being 
used for both in vitro and in vivo studies. Because it is so widely used, OVA 
epitopes are well known and many reliable read-out systems have been 
established, facilitating data collection and interpretation. In vitro it was 
shown for OVA-expressing recombinant MVA viruses that OVA is constantly 
secreted into the cell supernatant, allowing analysis of protein expression 
without affecting the cells. In terms of in vivo use, OVA has been established 
as a model antigen in various setting. Due to its well-studied epitopes, 
determination of OVA-specific T-cell responses is well established. At the 
same time, different OVA-expressing tumor cell lines exist (e.g. E.G7-OVA, 
B16 OVA). These tumor models, most of which are commercially available, 
enable efficacy testing of cancer vaccines for established tumors in mice 
(VIANELLO et al., 2006; FOTIN-MLECZEK et al., 2014). 
E.G7-OVA for example is a mouse T cell lymphoma cell line, that is stably 
expressing OVA epitopes. It was originally established as a tool to 
investigate antigen presentation and processing via MHC class I pathway 
and was derived from the mouse lymphoma cell line EL4 (MOORE et al., 
1988). Like most tumor cell lines, the E.G7-OVA is often used as a 
subcutaneous tumor model for therapy evaluation.  
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5. Objectives 
MVA is a well-established vector platform with an excellent safety profile 
and potent immune stimulatory capacity. However, the expression of 
several remaining immunomodulatory proteins might hamper the use of the 
vector’s full potential. The aim of this study was to investigate if inactivation 
of multiple immunomodulatory gene functions still allows for the construction 
of stable recombinant MVA vaccines and at the same time may lead to an 
improvement of the vector vaccine’s immunogenicity and efficacy. For that 
purpose, we targeted three candidate immunomodulatory proteins still 
produced by MVA and constructed two genetically modified candidate 
vector vaccines (MVA∆∆-OVA and MVA∆∆∆-OVA) in which two respectively 
all three of the chosen immunomodulatory genes are simultaneously 
deleted. This study describes:  
(i) the generation of the MVA∆∆-OVA and MVA∆∆∆-OVA candidate 
vector vaccines  
(ii) the genetic and functional analysis of MVA∆∆-OVA and MVA∆∆∆-
OVA in vitro in comparison to conventional recombinant MVA-
OVA  
(iii) the testing of immunogenicity and efficacy of MVA∆∆-OVA and 
MVA∆∆∆-OVA in vivo in comparison to conventional recombinant 
MVA-OVA  
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III. MATERIAL UND METHODS 
1. Antibodies 
Tab. 1: Primary Antibodies used for Western blot analysis 
Antibody Dilution Company 
mouse anti-GAPDH 1:10,000 Millipore, Darmstadt, Germany 
mouse anti-GAPDH 1:1,000 Thermo Fisher Scientific, Rockford, USA 
rabbit anti-Caspase 3 1:1,000 Cell Signaling Technology, Danvers, USA 
rabbit anti-chicken 
Ovalbumin 1:10,000 
Aviva Systems Biology 
Corporation, San Diego, USA 
rat anti-VACV C7 1:200 Hybridoma culture supernatant (BACKES et al., 2010) 
 
Tab. 2: Secondary Antibodies used for Western blot analysis 
Antibody Dilution Company 
Horseradish peroxidase 
(HRP) conjugated goat 
anti-rat polyclonal IgG 
1:20,000 BioLegend, San Diego, USA 
Horseradish peroxidase 
(HRP) conjugated goat 
anti-mouse IgG/IgM 
1:20,000 Jackson ImmunoResearch, West Grove, USA 
anti-mouse MFP 488 1:200 Mobitec, Berkheim, Germany 
anti-rat MFP 631 1:200  
Horseradish peroxidase 
(HRP) conjugated goat 
anti-rabbit IgG 
1:2,000 Cell Signaling Technology, Danvers, USA 
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 Tab. 3: Antibodies used for Immunostaining 
Antibody Dilution Company 
rabbit anti-VACV 1:2,000 Acris GmbH, Arnbruck, Germany 
goat anti-rabbit  1:5,000 Jackson ImmunoResearch, West Grove, USA 
 
Tab. 4: Antibodies used for ELISA 
Antibody Dilution Company 
Mouse IL-1β ELISA MAX™ 
Capture Antibody 1:200 BioLegend, San Diego, USA 
Mouse IL-1β ELISA MAX™ 
Detection Antibody 1:200 BioLegend, San Diego, USA 
Mouse IFN-γ ELISA MAX™ 
Capture Antibody 1:200 BioLegend, San Diego, USA 
Mouse IFN-γ ELISA MAX™ 
Detection Antibody 1:200 BioLegend, San Diego, USA 
 
2. Oligonucleotide primers 
Tab. 5: MVA specific oligonucleotide primers used for appropriate 
polymerase chain reactions 
Primers Sequence Size (bp) 
Del 1-F* 5‘-CTT TCG CAG CAT AAG TAG TAT GTC-3‘ 291 
Del 1-R* 5’-CAT TAC CGC TTC ATT CTT ATA TTC-3’  
Del 2-F* 5’-GGG TAA AAT TGT AGC ATC ATA TAC C-3’ 354 
Del 2-R* 5‘-AAA GCT TTC TCT CTA GCA AAG ATG-3‘  
III. Material und Methods    30 
Del 3-F* 5‘-GAT GAG TGT AGA TGC TGT TAT TTT G-3‘ 446 
Del 3-R* 5‘-GCA GCT AAA AGA ATA ATG GAA TTG-3‘  
Del 4-F* 5‘-AGA TAG TGG AAG ATA CAA CTG TTA CG-3‘ 502 
Del 4-R* 5’-TCT CTA TCG GTG AGA TAC AAA TAC C-3’  
Del 5-F* 5‘-CGT GTA TAA CAT CTT TGA TAG AAT CAG-3‘ 603 
Del 5-R* 5‘-AAC ATA GCG GTG TAC TAA TTG ATT T-3‘  
Del 6-F* 5’-CGT CAT CGA TAA CTG TAG TCT TG-3’ 702 
Del 6-R* 5‘-TAC CCT TCG AAT AAA TAA AGA CG-3‘  
008L-F 5‘-AAA GTT TAA TTT GTT GAC GAC GTA TG-3‘ 597 (wt) 
008L-R 5‘-CAT CAA ATA CAA AAT ATT CGA GCA AC-3‘ 450 (del) 
029L-F 5’-TCC ACT TCC AGA AAA TAT GG-3’ 838 (wt) 
029L-R 5‘-GCG AAG GAG ACC ACT ACA TC-3‘ 553 (del) 
184R-F 5‘-ATA TTC CGG CGT ATG AAT TG-3‘ 1163 (wt) 
184R-R 5‘-TTC GTC AAT TGT TTG TTG GAA G-3‘ 398 (del) 
wt: wildtype MVA, del: MVA deletion mutant; *(KREMER et al., 2012) 
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3. Media, additives and cell culture 
Tab. 6: media and additives used for cell culture maintenance and 
infection 
Media, additives and cell culture Supplier 
HEPES buffer (1 M) Sigma-Aldrich, St. Louis, USA 
Fetal calf serum (FCS) Gibco Invitrogen, Karlsruhe, Germany 
Fetal bovine serum (FBS), endotoxinfree Biochrom GmbH, Berlin, Germany 
Minimum Essential Medium Eagle (MEM) Sigma-Aldrich, St. Louis, USA 
MEM Non-essential amino acid solution Sigma-Aldrich, St. Louis, USA 
PBS Dulbecco (w/o Mg2+) PAN Biotech, Aidenbach, Germany 
Penicillin, Streptomycin (10,000U/ml, 
10mg/ml) 
Sigma-Aldrich, St. Louis, 
USA 
RPMI-1640 Gibco Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA  Sigma-Aldrich, St. Louis, USA 
VLE Dulbecco’s MEM (DMEM) Biochrom GmbH, Berlin, Germany 
Pathogen-free chicken eggs 
Charles River 
Laboratories, 
Massachusetts, USA 
VALO Biomedia GmbH, 
Osterholz-Schambeck, 
Germany 
 
4. Viruses 
4.1. Viruses used in this study 
The following viruses were used for this study: 
(i) MVA-OVA 
(ii) MVA∆184∆008-OVA (referred to as MVA∆∆-OVA) 
(iii) MVA∆184∆008∆029-OVA (referred to as MVA∆∆∆-OVA) 
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All recombinant, mutant and non-recombinant MVA viruses used in this 
study were based on the MVA clonal isolate F6. MVA F6 has been clonally 
isolated in limiting dilution passage experiments on chicken embryo 
fibroblasts (CEF) grown in 96-well tissue culture plates by Professor Gerd 
Sutter at LMU Munich in 1988. MVA F6 demonstrates clonal genetic 
homogeneity in comparison to its ancestor MVA stock virus as confirmed by 
analysis of viral DNA (Sutter 1990 LMU thesis; (MEYER et al., 1991). 
Recombinant MVA expressing chicken ovalbumin (MVA-OVA) was 
generated prior to the start of this study and served as standard 
recombinant MVA vector vaccine for control purposes (BRANDMÜLLER, 
LEHMANN, SUTTER, unpublished results). 
Deletion mutant MVA∆184∆008 was generated prior to the start of this study 
(ZARNIKO, STAIB, SUTTER, unpublished results) and served as starting 
material for the generation of the double/triple mutant-recombinant viruses 
MVA∆∆-OVA and MVA∆∆∆-OVA. 
ORF Length (AA)* Gene product 
008L 120 Interleukin-18 binding protein (vIL-18bp) 
029L 222 F1 protein 
184R 326 Interleukin-1β receptor (IL-1βR) 
 
Tab. 7: Modulatory genes in MVA analyzed in this study 
* (MEISINGER-HENSCHEL et al., 2007) 
 
4.2. Virus amplification, purification and handling 
All viruses were amplified on CEF in large (T175) flasks. Cell monolayers 
were infected and incubated for 3-4 days at 37° C until extensive cytopathic 
effects could be observed; then flasks were frozen at -20° C until further 
processing. 
For purification, cells were subjected to three freeze-thaw cycles before 
being centrifuged at 15,000 rpm for three hours at 4° C (Avanti J-26XP, 
Beckman Coulter). The supernatant was discarded completely and the 
resulting pellets were altogether resuspended in 30 ml Tris-buffer (10 mM 
Tris-HCl, pH 9.0). The pellet suspension was then sonicated three times for 
15 seconds and vortexed in between. The suspension was centrifuged at 
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1,200 rpm for five minutes at 4° C and the supernatant was carefully 
collected. The remaining pellet was once again resuspended in five ml Tris-
buffer and the process was repeated for 4-5 times. 
The collected supernatant was then purified by 36% sucrose gradient 
centrifugation. In plastic tubes, 15 ml sucrose was carefully overlaid with 20 
ml supernatant. Tubes were centrifuged at 15,000 rpm for 90 minutes at 4° 
C (OptimaTM LE-80K Ultracentrifuge, Beckman Coulter). 
The supernatant was discarded completely and the remaining pellets were 
carefully resuspended in 2-3 ml Tris-buffer (depending on the size of the 
pellets), aliquoted and stocks were long-term stored at -80° C. 
Before use, virus stocks were thawed on ice and sonicated three times for 
one minute each time. 
4.3. Virus titration and immunostaining 
To determine an accurate virus titer, all viruses were titrated three times in 
parallel. Titration was performed in 6-well plates on confluent CEF cell 
monolayers. Tenfold serial dilutions (10-1 to 10-9) were prepared with 
MEM/2% FCS/1% P/S and used to infect CEF cells in duplicate. Infected 
cells were incubated at 37°C for two hours, gently shook every 15 minutes. 
Thereafter, cells were washed once with PBS, fresh MEM/2% FCS/1% P/S 
was added and plates were incubated for 48 hours at 37° C. 
To fix the cell monolayer and permeabilize cells ice-cold acetone-methanol 
(1:1) was added and incubated at room temperature for five minutes. Upon 
removal, plates were air dried and blocked with PBS+3%FCS for 30 minutes 
at room temperature. 
To visualize plaques, plates were first incubated with primary rabbit anti-
VACV diluted 1:2,000 in PBS+3%FCS for one hour at room temperature on 
a rocking platform to ensure even antibody distribution. Plates were then 
washed three times with PBS before adding the secondary goat anti-rabbit 
diluted 1:5000. Plates were again incubated for one hour at room 
temperature on a rocking platform. They were then washed three times with 
PBS before adding 0.5 ml True BlueTM Peroxidase per well and incubated 
for 5-15 min at room temperature until stained foci became visible. Virus 
titer was determined by counting wells with 20-100 visible foci. Titer was 
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expressed as plaque forming units per milliliter (PFU/ml) by multiplying the 
number of counted foci by its dilution. 
4.4. Multi-step analysis of virus growth 
To determine virus growth, CEF and HaCat monolayers were infected with 
viruses at a multiplicity of infection (MOI) of 0.01 and incubated at 4°C for 
30 minutes (cold start). Thereafter, plates were washed once with cold PBS 
before adding warm medium and incubating them at 37°C. Subsequently, 
plates were frozen at different time points after infection (0, 4, 12, 24, 48, 
72h p.i.). Upon collection of all samples, they were subjected to three 
freeze-thaw cycles and titrated on CEF cells according to section III.4.3. 
Two multi-step growth curves were assembled for virus growth on 
permissive (CEF) and non-permissive (HaCat) cell lines. 
 
5. Cell culture 
5.1. Cultivation of permanent cells 
All permanent cell cultures were kept in a humidified incubator at 37° C with 
5% CO2. The proper culture medium was mixed with the amount of fetal calf 
serum (FCS) suitable for the cells plus 1% Penicillin/Streptomycine (P/S). If 
required, 1% HEPES and/or 1% non-essential amino acid solution (NEA) 
was also added. Cell cultures were split 1-2 times per week when dense, 
for which they were detached with Trypsin EDTA. For infection, cells were 
kept in their proper medium supplemented with only 2% FCS.  
Cell line Culture medium 
Human keratinocyte cell line 
(HaCat) 
VLE Dulbecco’s MEM (DMEM) + 
7% FCS + 1% P/S + 1% HEPES 
Mouse embryo fibroblast cell line 
(NIH3T3) 
VLE Dulbecco’s MEM (DMEM) + 
10% FCS + 1% P/S 
Human cervical carcinoma cell 
line (HeLa) 
Minimum essential eagle (MEM) 
medium + 7% FCS + 1% P/S + 1% 
NEA 
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5.2. Isolation and cultivation of primary cells 
5.2.1. Murine splenocytes 
Murine splenocytes were isolated from the spleens of C57BL/6 mice. After 
extraction, the spleens were kept in PBS to keep them from drying out, then 
homogenized by pressing them though a 70µm filter into a 50ml falcon tube. 
Subsequently, the cell suspension was centrifuged at 11,000 rpm for 5 
minutes at room temperature. The supernatant was discarded and the 
remaining cell pellet was resuspended in 3ml “red blood lysing buffer” to 
remove erythrocytes and incubated for 5 minutes at room temperature. After 
lysis, 7ml of PBS was added and the cell suspension was once again 
centrifuged at 11,000 rpm for 5 minutes at room temperature. The 
supernatant discarded and the cell pellet was resuspended in RPMI-1640 
medium supplemented with 10% FCS and the number of cells was 
determined in a Neubauer chamber. For cultivation and stimulation, 
splenocytes were seeded into cell culture plates at the desired density. 
5.2.2. Chicken embryo fibroblasts (CEF) 
CEF cells were freshly prepared once a week from pathogen-free chicken 
eggs that had been incubated for 11 days at 37° C prior to preparation. They 
were then maintained in Minimum essential eagle (MEM) medium 
supplemented with 10% FCS and 1% P/S. 
5.3. Cell count 
Cells were trypsinized, diluted 1:10 and stained with Trypan blue solution. 
Stained cells were counted in a Neubauer chamber. 
 
6. Polymerase chain reaction (PCR) 
To obtain PCR samples CEF monolayers were infected at an MOI of 5 and 
incubated for 1-2 days. Cells were harvested, centrifuged at 13,000 rpm for 
15 seconds and resuspended in 200 µl supernatant. The rest of the 
supernatant was discarded. Viral DNA was extracted and purified using the 
QIAmp DNA Mini Kit (Qiagen) following the enclosed protocol. 
Polymerase chain reaction (PCR) was performed with 50ng of DNA (2µl) 
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per sample and 23 µl of a PCR Master Mix. 
 
PCR Master mix composition: 
 
18.8 µl distilled water 
2.5 µl buffer (10x) 
0.5 µl  dNTP’s 
0.5 µl forward oligonucleotide primer 
0.5 µl reverse oligonucleotide primer 
0.2 µl Dynazyme II 
 
Specific oligonucleotide primers (as listed in Tab. 5) were used for the 
correspondent PCR reaction. The following thermocycling conditions were 
applied using the peqSTAR 2x thermocycler (PEQLAB Biotechnology 
GmbH): 
Del I-VI PCR   
Step Temperature Time 
Initial denaturation 95°C 3 minutes 
 95°C 30 seconds 
30 cycles 57°C 45 seconds 
 72°C 45 seconds 
Final extension 72°C 5 minutes 
Store 4°C forever 
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184R/008L PCR   
Step Temperature Time 
Initial denaturation 95°C 3 minutes 
 95°C 30 seconds 
30 cycles 57°C 45 seconds 
 72°C 75 seconds 
Final extension 72°C 5 minutes 
Store 4°C forever 
 
029L PCR 
  
Step Temperature Time 
Initial denaturation 95°C 3 minutes 
 95°C 30 seconds 
30 cycles 54°C 45 seconds 
 72°C 45 seconds 
Final extension 72°C 5 minutes 
Store 4°C forever 
 
After PCR, loading buffer (6x) was added to PCR products in the 
appropriate amount and samples were either analyzed via gel 
electrophoresis or stored at -20°C for later analysis.  
7. Gel electrophoresis 
PCR products were separated by size via gel electrophoresis. To visualize 
nucleic acid, Gel RedTM was added to the 1% agarose gel. DNA samples 
were loaded onto the gel together with an appropriate molecular weight 
marker. 1x TAE buffer was used as running buffer and nucleic acid was 
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visualized with ChemiDocTMMP Imaging system (Bio-Rad). Composition of 
buffers is listed in the appendix. 
 
8. Western blot analysis 
8.1. Verification of OVA expression  
To obtain samples for western blot analysis NIH3T3 cell monolayers were 
infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA at an MOI of 5. 
24h post infection, samples were collected and centrifuged at 13,000 rpm 
for 30 seconds. Supernatants were discarded; the remaining cell pellets 
were resuspended in SDS-lysis-buffer and heated to 95°C for five minutes, 
then kept on ice. Samples were loaded onto a 10% SDS-gel and the Color 
Protein Standard broad range (New England BioLabs) was used as a 
molecular weight marker. Protein electrophoresis was performed in 1x 
Tris/Glycine/SDS buffer at 120V for 90 minutes (Power Ease 500, Invitrogen 
life technologies). Proteins were then transferred to a 0.2 µm nitrocellulose 
blotting membrane (GE Healthcare Life Science) with 1x transfer buffer 
using the Trans Blot Turbo system (Bio-Rad). The membrane was blocked 
in Tris-buffered saline 0.1% Tween20 (TBS/T) supplemented with 5% 
nonfat dried milk powder overnight at 4°C. Thereafter, the blot was washed 
three times for 10 minutes each in TBS/T. 
After washing, the blot was simultaneously incubated with rabbit anti-OVA 
(1:10,000) and mouse anti-GAPDH (1:10,000) in TBS/T+2.5% milk for one 
hour at room temperature. The blot was washed three times for 10 minutes 
each in TBS/T before it was incubated with goat anti-rabbit HRP (1:2,000) 
and goat anti-mouse (1:20,000) in TBS/T+2.5% milk for one hour at room 
temperature. The blot was again washed three times for 10 minutes each in 
TBS/T before it was incubated with ClarityTM ECL Western Blotting substrate 
and analyzed using the ChemiDocTMMP Imaging System (Bio-Rad). 
8.2. Kinetic analysis of OVA expression 
CEF cells and NIH3T3 cells were infected with MVA-OVA at an MOI of 5. 
Samples were taken at different time points after infection (2, 4, 8, 12 and 
24h p.i.). As control, cells were also infected with MVA F6 at an MOI of 5 
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and sample was taken 24h post infection. Additionally, a mock control was 
also taken at 24h post infection.  All samples were centrifuged at 13,000 
rpm for 30 seconds, the supernatant was discarded and the cell pellet was 
resuspended in SDS-lysis-buffer and heated to 95°C for five minutes. 
Samples were stored at -80°C. Samples were loaded onto a 10% SDS-gel 
and the Color Protein Standard broad range (New England BioLabs) was 
used as a molecular weight marker.  
CEF and NIH3T3 samples were loaded onto two separate gels but 
electrophoresis was performed simultaneously in the same chamber 
Protein-electrophoresis, blotting and blocking was performed as described 
in III.8.1. 
Both blots were incubated with rabbit anti-OVA (1:10,000) and mouse anti-
GAPDH (1:10,000) as primary and goat anti-rabbit HRP (1:2,000) and goat 
anti-mouse (1:20,000) as secondary antibodies following the same protocol 
described in III.8.1. 
8.3. Examination of Caspase 3 activity 
HeLa cells were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA 
at an MOI of 10. Samples were taken 15 hours after infection. Cells were 
centrifuged, the supernatant was discarded and the cell pellet was 
resuspended in SDS-lysis-buffer and heated to 95°C for five minutes. After 
that, samples were kept on ice until loaded onto a 15% SDS-gel, the Color 
Protein Standard broad range (New England BioLabs) was used as a 
molecular weight marker. Protein electrophoresis was performed in 1x 
Tris/Glycine/SDS buffer at 120V for 90 minutes (Power Ease 500, Invitrogen 
life technologies). Proteins were then transferred to a 0.2 µm nitrocellulose 
blotting membrane (GE Healthcare Life Science) with 1x transfer buffer 
using the Trans Blot Turbo system (Bio-Rad). The membrane was blocked 
in Tris-buffered saline 0.1% Tween20 (TBS/T) supplemented with 5% 
bovine serum albumin (BSA) for one hour at room temperature. Thereafter, 
the blot was washed three times for 10 minutes each in TBS/T.  
The blot was incubated with rabbit anti-Caspase 3 (1:1000) in TBS/T 5% 
milk overnight at 4°C. The blot was then washed three times for 10 minutes 
each in TBS/T before it was incubated with goat anti-rabbit HRP (1:2,000) 
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in TBS/T 2.5% milk for one hour at room temperature. The blot was then 
again washed three times for 10 minutes each in TBS/T before it was 
incubated with ClarityTM ECL Western Blotting substrate and analyzed using 
the ChemiDocTMMP Imaging System (Bio-Rad). 
After that, the blot was washed again three times for 10 minutes each in 
TBS/T before it was incubated with mouse anti-GAPDH (1:20,000) and rat 
anti-C7 (1:200) diluted in 2.5% BSA for one hour at room temperature. The 
blot was washed three times for 10 minutes each in TBS/T and then 
incubated with anti-mouse MFP 488 (1:200) and anti-rat MFP 631 (1:200) 
diluted in 2.5% BSA for one hour at room temperature. Thereafter, the blot 
was washed three times for 10 minutes each in TBS/T and detected using 
the ChemiDocTMMP Imaging System (Bio-Rad).  
 
9. Functional assays 
9.1. IL-1β functional assay 
NIH3T3 cells were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-
OVA at an MOI of 5. After an incubation time of 30 minutes at 4°C (cold 
start), cells were washed once with cold PBS before warm medium was 
added. Supernatants were collected at different time points after infection 
(0, 4, 8 and 24h p.i.), treated with UV light (400 mJ, two minutes) and stored 
at -20°C until all samples had been collected. 
Supernatants were incubated in duplicate with murine recombinant IL-1β 
(BioLegend) at a final concentration of 1000 pg/ml for one hour at 37°C.  
Afterwards, supernatant were analyzed with a murine IL-1β enzyme-linked 
immunosorbent assay (ELISA) kit from BioLegend according to the protocol 
described in III.9.1.1. 
9.1.1. Mouse IL-1β ELISA 
NuncTM MaxiSorpTM ELISA plates were coated with 100 µl of Capture 
antibody (1:200) in 1x Coating buffer and incubated overnight at 4°C. 
Plates were washed four times with 300 µl PBS+0.05%Tween20 per well 
and then blocked by adding 200 µl assay diluent per well and incubating 
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them for one hour at room temperature on a rocking platform. After washing 
the plates four times with PBS+0.05%Tween20, 100 µl of supernatants and 
diluted mouse IL-1β standard was added per well and incubated for two 
hours on a rocking platform.  
The mouse IL-1β standard was reconstituted in 1x assay diluent to a final 
stock concentration of 145 ng/ml. For the assay, the stock solution was 
diluted to a concentration of 2000 pg/ml and six two-fold dilutions were 
performed with 1x assay diluent.  
Thereafter, plates were washed four times with 300 µl PBS+0.05%Tween20 
before 100 µl detection antibody (1:200) diluted in 1x assay diluent was 
added per well and incubated for one hour at room temperature on a rocking 
platform. After washing the plates four times with 300 µl 
PBS+0.05%Tween20, 100 µl of diluted Avidin-HRP (1:1000) were added 
per well and incubated for 30 minutes at room temperature with shaking. 
Plates were washed five times, soaking for 30 seconds per wash, before 
100 µl of substrate solution was added per well and incubated for 15 
minutes in the dark. Thereafter, 100 µl of stop solution was added and plates 
were analyzed using the Tecan SunriseTM microplate absorbance reader at 
450 nm. 
9.2. IL-18 functional assay 
CEF cells were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA 
at an MOI of 5. 24 hours after infection, supernatants were collected and 
treated with UV light (400 mJ) for two minutes. Afterwards, 100 µl of 
supernatants were preincubated in duplicate with 10ng/ml murine 
recombinant IL-18 for one hour at room temperature. Concanavalin A (Con 
A) was added to the preincubated supernatants at a concentration of 200 
ng/ml and the mix was used to stimulate freshly seeded murine splenocytes. 
Stimulated splenocytes were incubated at 37°C and supernatants were 
collected at 16 and 24 hours after infection.  
As a control, splenocytes were stimulated with Con A and cell supernatant 
without IL-18. Additionally, splenocytes were also stimulated with Con A and 
murine IL-18 without supernatant. 
Supernatants from stimulated splenocytes (w/ and w/o IL-18) were analyzed 
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with a murine IFN- γ ELISA kit from BioLegend according to the protocol 
described in III.9.2.1. 
9.2.1. Mouse IFN-γ ELISA 
NuncTM MaxiSorpTM ELISA plates were coated with 100 µl of Capture 
antibody (1:200) diluted in 1x Coating buffer and incubated overnight at 4°C. 
Plates were washed four times with 300 µl PBS+0.05%Tween20 per well 
and then blocked by adding 200 µl assay diluent per well and incubating for 
one hour at room temperature on a rocking platform. After washing the 
plates four times with PBS+0.05%Tween20, 100 µl of supernatants and 
diluted mouse IL-1β standard was added per well and incubated for two 
hours on a rocking platform.  
The mouse IFN-γ standard was reconstituted in 1x assay diluent to make 
the standard stock solution with a concentration of 110 ng/ml. For the assay, 
the stock solution was diluted to a concentration of 1000 pg/ml and six two-
fold dilutions were performed with 1x assay diluent.  
Thereafter, plates were washed four times with 300 µl PBS+0.05%Tween20 
before 100 µl detection antibody (1:200) diluted in 1x assay diluent was 
added per well and incubated for one hour at room temperature on a rocking 
platform. After washing the plates four times with 300 µl 
PBS+0.05%Tween20, 100 µl of diluted Avidin-HRP (1:1000) were added 
per well and incubated for 30 minutes at room temperature with shaking. 
Plates were washed five times, soaking for 30 seconds per wash, before 
100 µl of substrate solution was added per well and incubated for 15 
minutes in the dark. Thereafter, 100 µl of stop solution was added and plates 
were analyzed using the Tecan SunriseTM microplate absorbance reader at 
450 nm. 
9.3. Apoptosis assay 
To monitor apoptosis upon infection, HeLa cells were infected at an MOI of 
5 and analyzed via western blot analysis and fluorescent staining of fixed 
cells. 
9.3.1. Caspase 3 western blot analysis 
HeLa cells were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA 
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at an MOI of 5 in duplicate in a 24-well-plate. As a positive control, cells 
were treated with 1µM Staurosporine. 
15 hours after infection western blot samples were collected and analyzed 
as described in III.8.3. 
9.3.2. Fluorescent staining of fixed cells 
HeLa cells were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA 
at an MOI of 5 in a 96-well-plate. Uninfected cells served as mock control. 
15 hours after infection, medium was removed and cells were fixed with 4% 
paraformaldehyde (50 µl per well) for 60 minutes on ice. After fixation, the 
plate was washed once with 200 µl PBS per well before cells were 
permeabilized with 0.5% TritonX-100 (100 µl per well) for 15 minutes at 
room temperature. The plate was washed again with PBS and then cells 
were incubated with 300 µM 4′,6-Diamidin-2-phenylindol (DAPI) in the dark 
for 7 minutes at room temperature on a rocking platform. Cells were washed 
twice with PBS and fluorescent cell nuclei were analyzed at 20x and 40x 
magnification using the KEYENCE fluorescence microscope. 
 
10. In vivo experiments 
All in vivo experiments were performed externally in cooperation with our 
collaborators from Boehringer Ingelheim at the research facility in Biberach 
under the guidance of Prof. Dr. Klaus Erb (efficacy study) and Dr. 
Aleksandra Kowalczyk (immunogenicity study). 
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IV. RESULTS 
1. Construction of viruses 
The first part of this study focuses on the construction of MVA∆∆-OVA and 
MVA∆∆∆-OVA on the basis of MVA∆184∆008. 
1.1. Introduction of Ovalbumin 
In a first step of construction, we introduced OVA into deletion III (Del III) of 
the double mutant MVA∆184∆008. 
 
 
Fig. 6: Scheme of recombinant MVA generation. Locations of MVA’s six 
major deletion sites (I-IV) are indicated. Ovalbumin (under transcriptional 
control of PmH5) was introduced into Del III via homologous recombination. 
flank-1/flank-2: nucleotide sequences flanking MVA’s Del III, flank-1r: flank-
1 repeat  
  
We synthesized the gene encoding OVA and cloned it into our standard 
pIIIH5redK1L plasmid where it was put under transcriptional control of the 
strong early/late modified vaccinia promoter PmH5 (WYATT et al., 1996). 
We then introduced it into MVA’s Del III via standard homologous 
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recombination using our established standard methodology (Fig. 6). 
Deletion of the marker gene mCherry occurred during plaque passaging 
(SHANER et al., 2004; KREMER et al., 2012).  
1.2. Deletion of the 029L gene 
Using the previously constructed recombinant MVA∆∆-OVA as starting 
material, the second part of construction was to construct a triple mutant 
recombinant MVA virus, in which the 029L gene is additionally deleted. 
For deletion of the 029L gene, we performed a transient dominant selection 
(TDS) (FALKNER & MOSS, 1990) on CEF cells as shown in Fig. 7. The 
plasmid contained a truncated version of the 029L gene along with the 029L 
gene’s original flanking sites. For selection, Escherichia coli guanine 
phosphoribosyltransferase (gpt) was added to the plasmid as a dominant 
selectable marker, which enables resistance to mycophenolic acid (MPA) 
(FALKNER & MOSS, 1990). 
 
 
Fig. 7: Scheme of transient dominant selection (TDS). ORF: Open 
reading frame, ∆F1L: truncated F1L gene, F1/F1’: flanking site 1, F2/F2’: 
flanking site 2, gpt: Escherichia coli guanine phosphoribosyl-transferase 
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For selection, we induced selection pressure directly after transfection by 
supplementing MEM 2% FCS with gpt-selection medium consisting of 
0.25% MPA (10mg/ml in 0.1 N NaOH), 2,5% xanthine (10mg/ml in 0.1 N 
NaOH) and 0.15% hypoxanthine (10mg/ml in 0.1 N NaOH), sterile filtered. 
After four rounds of consecutive plaque picking under selection pressure, 
we removed selection pressure, which results in a subdivision of the virus 
population into non-recombinant and recombinant MVA at a 50:50 ratio. 30 
plaques were isolated, amplified and screened via Polymerase chain 
reaction (PCR) for the truncated 029L gene. 
 
2. Genetic characterization of constructed viruses 
The second part of this study focuses on the genetic characterization of our 
constructed recombinant mutant MVA viruses. A series of experiments was 
conducted to affirm correct insertion of OVA along with confirmation of 
genetic purity, successful gene deletion and backbone integrity 
2.1. Verification of correct insertion of Ovalbumin gene 
All three recombinant MVA viruses used in this study where generated via 
homologous recombination of an OVA encoding gene into Del III. To verify 
the correct insertion of the OVA gene into Del III, an oligonucleotide primer 
set specific for the deletion was used for a PCR analysis. This primer set 
was previously established and designed to flank the deletion sites and 
allow for their amplification with a distinct product size (KREMER et al., 
2012). 
The expected size of the amplified fragment was calculated by adding the 
length of the nucleotide sequence of OVA to the known size of the existing 
Del III. 
The OVA specific fragment was detectable in all recombinant mutant and 
non-mutant MVA viruses (1736 bp) and confirmed correct insertion of OVA 
into Del III. MVA F6 served as a control and showed a fragment in size 
according to the Del III without insert (446 bp). The same fragment was 
absent in all recombinant MVAs, confirming genetic purity. A negative 
control was also used in which DNA was replaced by water, to ensure the 
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PCRs specificity (Fig. 8). 
 
 
Fig. 8: PCR analysis to verify correct insertion of OVA into Del III. PCR 
reactions were performed with viral DNA and a nucleotide primer set 
specific for MVA’s Del III. Expected sizes: Del III: 446 bp, Del III + OVA: 
1736bp; Marker (M), water control without viral DNA (WC), sizes in 
kilobases (kb) 
 
2.2. Verification of genetic modifications and MVA backbone 
integrity 
Recombinant MVAs were also tested to verify the specific genetic 
modifications that were introduced into MVA’s backbone genome. For that 
purpose, three sets of oligonucleotide primers were designed to flank the 
three genes in question (008L, 029L, 184R) and amplify a specific fragment 
with a predetermined distinct size. PCRs were performed for MVA∆∆-OVA 
(Fig. 9A) and MVA∆∆∆-OVA (Fig. 9B) and MVA-OVA was used as a control 
to verify correct size of the intact gene. The expected sizes of all fragments 
were calculated by subtracting the deleted nucleotide sequence from the 
size of the corresponding intact gene. 
Presence of a predicted smaller fragment was detectable for all modified 
genes when expected and confirmed successful deletion of the genes. 
Water served as a negative control to ensure specificity. 
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Fig. 9: PCR analysis to verify genetic modifications. PCR reactions were 
performed with oligonucleotide primer sets specific for the two respectively 
three modified genes and viral DNA of MVA∆∆-OVA (A) and MVA∆∆∆-OVA 
(B) Expected sizes: 008L: 597 bp, ∆008L: 450 bp, 029L: 838 bp, ∆029L: 553 
bp, 184R: 1163 bp, ∆184R: 398 bp;   Marker (M), water control without viral 
DNA (WC), sizes in kilobases (kb). 
 
Furthermore, we tested our MVA viruses for genetic integrity of the MVA 
backbone. For that, primer sets specific for MVAs six major deletion sites 
(Del I-VI), which had previously been established by our lab, were used and 
PCRs were performed for all three recombinant MVAs and MVA F6 as a 
control. All primer sets were designed to flank the major deletion sites and 
each set amplifies one fragment with a distinct size in ascending order from 
Del I to Del VI (Fig. 10) (KREMER et al., 2012). All MVA viruses showed 
fragments in the expected sizes. All recombinant MVA viruses showed an 
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expected fragment bigger in size for Del III due to insertion of OVA. 
Additionally, MVA∆∆-OVA and MVA∆∆∆-OVA showed no fragment for Del 
II which was expected due to their MVA II new backbone (STAIB et al., 
2003). 
 
 
Fig. 10: Genetic integrity of recombinant MVAs. PCR reactions were 
performed with viral DNA and nucleotide primer sets specific for MVAs Del 
I-VI. Expected sizes: Del I: 291 bp, Del II: 354 bp, Del III: 446 bp/1736 bp, 
Del IV: 502 bp, Del V: 603 bp, Del VI: 702 bp; marker (M), control without 
viral DNA (WC), sizes in kilobases (kb). 
 
2.3. Recombinant MVAs stably express OVA 
After verification of successful insertion of OVA into Del III, we checked 
expression of the protein via Western blot analysis.  
2.3.1. Comparative kinetic analysis of OVA expression in chicken 
and mouse cell line 
To determine the time point after infection that is best to check OVA 
expression in cell culture, a kinetic analysis of OVA expression was 
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performed in CEF cells (Fig. 11A). Additionally, a comparative kinetic 
anaylsis was performed in NIH3T3 cells (Fig. 11B) to verify OVA expression 
in murine cells with regard to future experiments in mouse models. 
 
Fig. 11: Kinetic analysis of OVA expression in NIH3T3 and CEF cells. 
CEF (A) and NIH3T3 (B) were infected with MVA-OVA at an MOI of 5. Cells 
were harvested at the indicated time points (hours post infection, hpi) and 
lysates were analyzed for OVA and GAPDH expression. Mock (m) and MVA 
F6 (F6) infected cells served as controls and samples were obtained 24 hpi.   
 
CEF cells respectively NIH3T3 cells were infected with MVA-OVA at an MOI 
of 5 and samples were taken at different time points post infection MVA-F6 
infected cells and uninfected cells (mock) served as a negative control and 
both samples were taken 24h post infection. Lysates were analyzed by 
western blotting using anti-OVA and anti-GAPDH specific antibodies. OVA 
expression was confirmed (46 kDa) with a first signal detectable at 4 hours 
p.i. (Fig. 11) and continued with a steady increase over the course of 
infection and a strong signal 24 hours p.i.. Expression levels were 
comparable to slightly stronger in NIH3T3 cells (Fig. 11). GAPDH (38 kDa) 
was detectable in all samples and confirmed cellular input (Fig. 11). 24hpi 
was chosen as the time point for obtaining western blot samples in further 
experiments. 
2.3.2. Western Blot analysis of OVA expression  
After confirmation and kinetic analysis of OVA expression of MVA-OVA, the 
CEF cells
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next step was to confirm OVA expression in all our recombinant MVA 
viruses. CEF cells were infected with MVA-OVA, MVA∆∆-OVA, MVA∆∆∆-
OVA and MVA F6 at an MOI of 5 and samples were obtained 24h p.i. 
according to the kinetic analysis. Lysates were analyzed by western blotting 
with anti-OVA and anti-GAPDH specific antibodies (Fig. 12).  
 
 
Fig. 12: Verification of OVA expression by recombinant MVAs. CEF 
cells were infected with the indicated viruses at an MOI of 5 and samples 
were taken 24h post infection. Lysates were analyzed by western blot for 
OVA (upper lane) and GAPDH (lower lane) expression. MVA-F6 and 
uninfected cells (mock) served as negative control. 
 
We detected OVA-specific (46 kDa) bands in all samples infected with 
recombinant MVA viruses but not for MVA-F6 and mock controls, confirming 
OVA expression (Fig. 12, upper lane). GAPDH (38 kDa) was detectable in 
all samples and confirmed cellular input (Fig. 12, lower lane). 
2.4. Multi-step growth kinetic of recombinant MVAs 
To confirm MVA’s safety profile after genetic modifications and insertion of 
OVA, its replication capacity and limited host range was determined in cell 
culture. This confirmation is important to verify that recombinant MVA 
viruses can indeed be handled under biosafety level 1 conditions like non-
recombinant MVA (ZKBS, 2002). 
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Fig. 13: Multi-step growth analysis of recombinant MVAs. Virus growth 
was evaluated over the course of 72h under permissive (CEF   ) and non-
permissive (HaCat ∆) conditions. MVA F6 was used as wildtype control 
virus. 
 
In this context, the inability to productively replicate in cells of human origin 
is an important feature of MVA (MAYR & MUNZ, 1964; SUTTER & MOSS, 
1992; BLANCHARD et al., 1998). Therefore, a multi-step analysis of virus 
growth was performed for all recombinant MVA viruses along with MVA F6 
in HaCat cells, which is an established laboratory human cell line. During a 
period of 72h of infection, none of the tested viruses was able to productively 
replicate in HaCat cells (Fig. 13) At the same time, virus growth was also 
analyzed in CEF cells, which are permissive for MVA infection. Here, all 
viruses tested were able to productively infect CEF cells and titers steadily 
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increased during the course of infection with a maximum of 10.000-fold 
increase after 72 hours (Fig. 13).  
 
3. Functional characterization of constructed viruses 
The previously conducted molecular characterization confirmed genetic 
purity, successful gene deletion and backbone integrity along with 
successful and efficient expression of OVA. Furthermore, all tested 
recombinant MVA viruses were shown to be unable to productively 
propagate on human HaCat cells. The third part of this study focuses of the 
functional characterization of the constructed viruses. 
3.1. Mutant MVA viruses lack vIL-1βR expression 
To confirm the deletion of the vIL1βR on a functional level, the missing 
binding activity of the vIL-1βR in the modified viruses used for this study 
was assessed in the supernatant of infected cells. For that, NIH3T3 cells 
were infected with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA at an MOI 
of 5 and supernatants of infected cell cultures were collected at 4h, 8h and 
24h post infection. To investigate the presence respectively absence of the 
vIL-1βR, murine IL-1β (mIL-1β) was added (1000 pg/ml) to the supernatants 
and incubated for one hour at 37° C. After that, supernatants were subjected 
to a mIL1β-specific ELISA, which is only able to recognize unbound mIL-1β, 
whereas receptor-bound mIL-1β is no longer detectable. Therefore, 
presence of vIL-1βR and its binding to mIL-1β will decrease levels of 
detectable mIL-1β in the supernatant.   
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Fig. 14: Expression and binding activity of vIL-1βR after infection of 
NIH3T3 cells. NIH3T3 cells were infected with the indicated viruses at MOI 
of 5. Supernatants were harvested at the indicated time points post infection 
and incubated with mIL-1β. Binding activity was analyzed by ELISA. The 
supernatant of uninfected cells was used as a control.  
*** P < 0,001 
 
All analyzed samples showed high levels of free mIL-1β at 4h post infection, 
thus no expression and binding activity of the receptor was detectable. 
However, in the samples taken 8h and 24h post infection, a significant 
decrease of free mIL-1β was observed in supernatants of MVA-OVA 
infected cells. In contrast, supernatants of cells infected with MVA∆∆-OVA 
and MVA∆∆∆-OVA maintained high levels of free mIL-1β (Fig. 14). 
comparable to mIL-1β levels detected in the mock control. This confirmed 
expression and binding activity of a vIL-1βR in MVA-OVA along with its late 
expression during the virus life cycle. Furthermore, functional absence of 
the receptor was confirmed for both mutant viruses, MVA∆∆-OVA and 
MVA∆∆∆-OVA.   
3.2. Mutant MVA viruses lack vIL-18bp expression  
To confirm the missing expression and study the missing binding activity of 
the vIL-18bp in the modified viruses used for this study, we conducted an 
analysis of supernatants of infected cells. For that, CEF cells were infected 
with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA at an MOI of 5 and 
supernatants were collected 24h p.i.. To check for the presence of the vIL-
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18bp in the supernatants, they were then incubated with recombinant 
mouse IL-18 (10 ng/ml) for one hour, before stimulating murine spleoncytes 
with these supernatants in combination with Concanavalin A (Con A) (200 
ng/ml). Unbound IL-18 in combination with Con A has previously been 
described to stimulate IFN-γ production in splenocytes (BOHN et al., 1998). 
Hence, the supernatants from stimulated spleconcytes were collected 16h 
(Fig. 15 A) and 24h (Fig. 15 B) post stimulation and analyzed for IFN-γ 
production via ELISA. Presence of vIL-18bp in the supernatant should bind 
to free IL-18 and significantly decrease levels of IFN-γ in stimulated murine 
splenocytes. To ensure specificity of IL-18 dependent stimulation, 
splenocytes were also stimulated with supernatants treated only with Con A 
but not with IL-18 (Fig. 15 A and B). 
The supernatants of splenocytes stimulated with IL-18, Con A and 
supernatants from either MVA∆∆-OVA or MVA∆∆∆-OVA infected CEF cells 
show high levels of IFN-γ after 16h and 24h post stimulation (Fig. 15 A and 
B). The same was observed for the mock control, i.e. splenocytes stimulated 
with IL-18, Con A and supernatant from uninfected CEF cells. However, 
splenocytes stimulated with IL-18, Con A and supernatant from MVA-OVA 
infected CEF cells show significantly lower levels of IFN-γ in the supernatant 
after both 16h and 24h post stimulation (Fig. 15 A and B).  
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Fig. 15: Expression and binding activity of IL-18BP. CEF cells were 
infected with the indicated viruses at an MOI of 5 and supernatants were 
collected 24h p.i.. Collected supernatants were then incubated with mIL-18 
and used to stimulate freshly prepared murine splenocytes in the presence 
of Con A. Supernatants from splenocytes were collected 16h (A) and 24h 
(B) after stimulation and subjected to IFN-γ ELISA. ** P < 0.005 
 
Splenocytes that were only stimulated with supernatants and Con A showed 
only low levels of IFN-γ in the supernatant, ensuring that observed IFN-γ 
production relies on IL-18 stimulation (Fig. 15). 
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This experiment confirmed that MVA-OVA produces a soluble vIL-18bp and 
that that binding protein is able to bind mature IL-18. At the same time, IL-
18 that is bound to vIL-18bp is no longer biologically active, thus no 
stimulation of splenocytes occurred. Both knock-out viruses however were 
unable to produce such a binding protein, allowing IL-18 to induce IFN-γ 
production in the presence of Con A at 16h and 24h post stimulation, 
confirming functional absence of the binding protein in both viruses.  
3.3. MVA∆∆∆-OVA induces apoptosis in infected cells 
To confirm successful deletion of the F1 protein in MVA∆∆∆-OVA on a 
functional level, we conducted two different experiments, focusing on the 
protein’s known ability to block apoptotic cell death in MVA infected cells 
(WASILENKO et al., 2003).  
3.3.1. Lack of F1 protein increases activation of Caspase-3 during 
MVA infection 
Caspase-3 is one of three terminal caspases that upon activation lead to 
apoptotic cell death (Fig. 4). MVA’s F1 protein however blocks activation of 
Caspase-3 by preventing cleavage of the pro-enzyme (pro-Casp-3) into its 
active form. To confirm that lack of F1 protein allows for cleavage and thus 
leads to activation of pro-Casp-3, HeLa cells were infected with MVA-OVA, 
MVA∆∆-OVA and MVA∆∆∆-OVA at an MOI of 5 and samples for western 
blot analysis were obtained 15h post infection. As a positive control, cells 
were stimulated with Staurosporine, a known inducer of apoptosis, whereas 
untreated cells served as negative control.  
Samples from uninfected cells along with samples from cells infected with 
MVA-OVA and MVA∆∆-OVA all showed strong signals for full-length pro-
Casp-3 (35 kDa). Samples obtained from cells stimulated with 
Staurosporine or infected with MVA∆∆∆-OVA on the other hand showed a 
clear reduction in signal strength for pro-Casp-3. At the same time, this was 
associated with the appearance of a much stronger signal for activated 
Caspase-3 (17 kDa) (Fig. 16). These results indicate that lack of F1 protein 
indeed leads to an activation of Casp-3 though cleavage of pro-Casp-3, 
making way for apoptotic cell death in infected cells.  
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Fig. 16: Cleavage of pro-Casp-3 upon MVA infection. HeLa cells were 
infected with the indicated viruses at an MOI of 5. Samples were taken 15h 
p.i. and checked for cleavage of Caspase-3 by western blotting. Uninfected 
cells (mock) served as negative control; Cells treated with Staurosporine 
were used as positive control; GAPDH served as loading control, C7L 
served as control for viral load. 
 
3.3.2. Lack of F1 protein causes karyorrhexis in infected cells 
One distinct event of apoptotic cell death is the fragmentation of the cell’s 
nucleus (ZAMZAMI & KROEMER, 1999). To visualize the effect of the 
missing F1 protein on nuclear morphology, we examined the nuclei of MVA 
infected cells and screened for signs of fragmentation. To do so, we infected 
HeLa cells with MVA-OVA, MVA∆∆-OVA and MVA∆∆∆-OVA at an MOI of 
5. 15h post infection, cells were fixed and nuclei were stained to visualize 
karyorrhexis. Uninfected cells were used as a control (Fig. 17).  
DAPI staining of cell nuclei of uninfected cells showed no signs of cell 
nucleus fragmentation. At the same time, nuclei of cells infected with MVA-
OVA and MVA∆∆-OVA also showed no signs of karyorrhexis. However, a 
large proportion of cells infected with MVA∆∆∆-OVA showed nuclear 
fragmentation (Fig. 17). These results confirm that lack of F1 protein not 
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only allows for activation of Casp-3, but also that cells infected with viruses 
lacking the F1 protein are able to undergo apoptosis. 
 
Fig. 17: Induction of apoptosis by MVA∆∆∆-OVA. DAPI staining of cells 
infected with the indicated viruses at an MOI of 5. Nuclei were stained 15h 
p.i.. Uninfected cells (mock) were used as a negative control. 
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4. In vivo evaluation of immunogenicity and efficacy 
Following the genetic and functional characterization of the constructed 
MVA viruses, this last part of the study focuses on the comparison of our 
constructed vaccine candidates in vivo. For that purpose, we evaluated the 
immunogenicity and efficacy of our constructs in two separate mouse 
models. 
4.1. Evaluation of immunogenicity 
To determine immunogenicity, we quantitatively compared immune 
responses induced by our vaccine candidates. For that purpose, C57BL/6 
mice were grouped into groups of five. All mice were vaccinated 
intramuscularly at day 0 (prime) with 107 PFU of either MVA-OVA, MVA∆∆-
OVA, MVA-∆∆∆-OVA or PBS as control. At day 14 p.i., all mice received a 
second dose of the same virus/PBS as boost. At day 21 p.i., mice were 
sacrificed, sera and spleens were collected and samples were analyzed for 
the presence of OVA-specific T-cells.  
 
The experiments were performed externally in cooperation with our 
collaborators from Boehringer Ingelheim at the research facility in Biberach 
under the guidance of Dr. Aleksandra Kowalczyk. 
4.1.1. Induction of OVA-specific T-cells 
To determine if a prime/boost immunization induces OVA-specific T-cells, a 
FACS analysis of splenocytes was performed. SIINFEKL was used as an 
OVA-specific peptide to stimulate CD8+ T-cells and determine the amount 
of CD8+ T-cells capable of being activated.  
 
As expected, in mice immunized with PBS as control no OVA-specific CD8+ 
T-cells were detectable among the T-cell population. In contrast, all mice 
mounted OVA-specific T-cell responses when immunized with any of the 
recombinant MVA vaccines. This response is highly significant for all MVA 
vaccinated groups in comparison to the control group that received PBS as 
mock vaccine (Fig. 18). Overall, the three MVA-OVA vaccines induced 
comparable levels of OVA-specific T-cells. Yet, we observed a slightly 
higher amount of OVA-specific T-cells in mice immunized with MVA∆∆-OVA 
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compared to the other groups, albeit no significant increase could be 
detected (Fig. 18).   
These results show that our mutant MVA viruses are indeed able to induce 
CD8+ T-cells specific for OVA after prime/boost vaccination at levels that 
are at least comparable to those elicited by non-modified recombinant MVA.  
 
 
 
Fig. 18:  Analysis of SIINFEKL specific T-cells. Mice were immunized 
i.m. in a prime/boost setting with 107 PFU of the indicated viruses (n=5). 
Mice inoculated with PBS were used as control. 21 days p.i., the amount of 
SIINFEKL-specific CD8+ T-cells was determined using flow-cytometry 
(FACS); values are given as mean with SEM. Statistically relevant 
differences between results are indicated with **, P<0.01. 
 
4.2. Evaluation of efficacy 
For comparing efficacy, all three candidate vaccines were tested in a 
therapeutic setting using an E.G7 OVA-expressing murine tumor model. 
E.G7 is a murine T-cell lymphoma cell line that, when injected 
subcutaneously, leads to the formation of a solid tumor with tumor cells that 
stably express OVA-epitopes as a unique antigen (ZHOU et al., 1992). 
Therefore, OVA-specific immune responses can affect tumor growth. With 
that said we decided to compare efficacy of our candidate vaccines by 
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evaluating and comparing the outcome of therapeutic immunizations after 
tumor challenge. 
For that purpose, female C57Bl/6 mice were grouped into seven 
experimental groups with 12 animals per group. All mice received 0.5x106 
E.G7–OVA tumor cells subcutaneously into the flank at day 0. When tumors 
were palpable at day six, mice were intramuscularly vaccinated once with 
MVA-OVA, MVA∆∆-OVA, MVA-∆∆∆-OVA or PBS as control. For dosage 
evaluation, two groups always received the same vaccine candidate with 
either 106 PFU or 107 PFU (Fig. 19A). After vaccination, tumor growth and 
survival rate of each group were monitored and evaluated at least twice a 
week until the end of the experiment at day 30 (Fig. 19B). Tumor growth 
was evaluated by determining tumor volume using a caliper. Mice were 
sacrificed once they reached a previously set end point respectively at the 
end of the experiment.  
   
 
Fig. 19: E.G7–OVA Tumor model. Grouping of mice (A) and timetable of 
experimental setup (B). 
 
The experiment was performed externally in cooperation with our 
collaborators from Boehringer Ingelheim at the research facility in Biberach 
under the guidance of Prof. Dr. Klaus Erb. 
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4.2.1. Immunization slows tumor growth and prolongs survival 
Median survival for PBS vaccinated mice was 21 days.  
Of the groups vaccinated with 106 PFU, mice vaccinated with MVA-OVA 
showed median survival of 25.9 days whereas mice vaccinated with 
MVA∆∆-OVA showed median survival of 25.95 days. The longest median 
survival was observed for animals vaccinated with MVA∆∆∆-OVA with 27 
days. Of the groups that were vaccinated with a one log higher dose of 
MVAs (107 PFU) median survival was 25.075 days for MVA-OVA, 25.125 
days for MVA∆∆-OVA and 25.175 days for mice vaccinated with MVA∆∆∆-
OVA. 
In terms of survival rate, a significantly prolonged survival was observed for 
groups that received any of the recombinant MVAs compared to the PBS 
receiving control group (p<0.001). This could be observed for both dosages 
tested (Fig. 20 A and B). However, out of the groups that received 106 PFU, 
no statistical significances were observed between the group that received 
MVA-OVA and the groups that received either MVA∆∆-OVA or MVA∆∆∆-
OVA. Nevertheless, survival rate was significantly higher for animals that 
received 106 PFU of MVA∆∆∆-OVA compared to animals that received 106 
PFU of MVA∆∆-OVA (p<0.05). At the same time, out of the groups that 
received 107 PFU, no statistical significances were observed between any 
of the groups that received recombinant MVAs.  
Concerning tumor growth, all groups that received a recombinant MVA-
vaccine show significantly smaller tumor volumes starting at day 15 
(p<0.001) when compared to the control group. However, no statistical 
differences could be detected between groups that received different 
viruses, except at day 26, where tumor volume was significantly lower for 
animals that received 106 PFU MVA∆∆∆-OVA compared to animals that 
received 106 PFU MVA∆∆-OVA (p<0.05) (Fig. 20 A and B).  
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Fig. 20: Efficacy of modified recombinant MVA-OVA vaccine 
candidates. C57Bl/6 mice (n=12) were inoculated with 0.5x106 E.G7–OVA 
cells s.c.. When tumors were palpable at day 6 post inoculation, mice were 
vaccinated with either 106 PFU (A) or 107 PFU (B) of the indicated viruses. 
One group received PBS as control. Tumor growth and survival rate were 
analyzed over time. p.v. = post vaccination. Values of tumor volume are 
shown as mean +/- SEM+.  
 
Taken together, these results indicate that a therapeutic vaccination of mice 
with recombinant MVA vector vaccines is successful and is capable of 
significantly increasing survival rate while significantly slowing tumor 
growth. Outcomes of both dosages were similar, indicating that 106 PFU 
was already sufficient to induce a potent immune response that was able to 
decelerate tumor growth and prolong survival. However, no significant 
differences could be detected between efficacies of wildtype MVA-OVA 
compared to our constructs. Nevertheless, MVA∆∆∆-OVA performed 
significantly better compared to MVA∆∆-OVA when given at a dosage of 106 
PFU.  
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V. DISCUSSION 
Prophylactic vaccines against various pathogens are generally very 
effective and protect against all types of infectious diseases. Therapeutic 
cancer vaccines on the other hand are much less successful. One reason 
for that is the occurrence of antigens. Pathogen-targeting vaccines can be 
based on pathogen-specific non-self antigens. Such antigens are naturally 
immunogenic and very potent in eliciting a strong immune response. With 
cancer vaccines, antigen identification is much more complicated. Target 
antigens need to be tumor-specific and unique to or at least overexpressed 
on tumor cells as compared to healthy cells 
(https://www.ncbi.nlm.nih.gov/pubmed/25483639). Over the last years, the 
identification of possible tumor antigens has been heavily studied and to 
date, several promising antigens for different types of cancer have been 
detected. However, successful therapeutic cancer vaccination doesn’t only 
require the right antigen. Tumors embed themselves in their own 
microenvironment, in which the immune system is heavily down regulated. 
Therefore, the immune responses elicited need to be strong enough to 
overcome immune evasion of the tumor. In that context, the development of 
viral vector based therapeutic cancer vaccines has gained considerable 
interest over the years. 
This study focused on the improvement of MVA as a viral vector, especially 
for immunotherapeutic approaches. For that reason, we constructed two 
genetically modified recombinant MVA viruses expressing OVA as a model 
antigen. Both constructs (MVA∆∆-OVA and MVA∆∆∆-OVA) were deleted in 
two (MVA∆∆-OVA) respectively three (MVA∆∆∆-OVA) immunoregulatory 
genes in order to potentially boost the vector’s efficacy. MVA-OVA served 
as a recombinant non-modified control virus. At first, a detailed genetic and 
functional in vitro characterization was performed. Replication analysis of 
constructs in comparison to MVA-OVA as well as wildtype MVA F6 showed 
no lack of replication capacity in susceptible primary CEF cells. In contrast, 
both constructs were unable to productively replicate in human HaCat cells 
as expected, confirming no change in the biosafety level 1 profile of MVA. 
Furthermore, it was shown that both constructs were able to stably express 
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OVA at levels equal to MVA-OVA in both chicken and murine cell lines. 
Successful deletion of the desired genes (184R, 029L, 008L) in both 
constructs was genetically confirmed with no change in backbone integrity. 
The results confirmed that simultaneous deletion of two respectively three 
immunomodulatory genes from the MVA genome still allows for the 
construction of a stable recombinant MVA. Furthermore, deletions were also 
ratified on a functional level in vitro. Lack of the F1L protein (029L) was 
shown to increase apoptosis in infected cells. Absence of the vIL-18bp 
(008L) and IL-1βR (184R) was confirmed through missing binding activity 
of the respective Interleukin. Additionally, immunogenicity and efficacy of 
the constructs was tested in vivo using a prime/boost vaccination study and 
a murine tumor model. The immunogenicity study revealed that both 
constructs are able to elicit antigen-specific CD8+ T-cells at levels 
comparable to non-mutated MVA-OVA. Results from the efficacy study 
reinforced MVA’s therapeutic potential with delayed tumor growth and 
longer survival of vaccinated compared to non-vaccinated mice. However, 
in this particular setting, no significant differences were detectable between 
immunogenicity and efficacy of non-mutated MVA and our two mutated 
constructs.  
Why is the development of new alternative cancer therapies 
important? 
Today, cancer is among the leading causes of death worldwide (Fig. 21). 
According to the WHO, 8.8 million people have died from cancer in 2015 
alone. That means, in 2015 almost 1 in 6 deaths globally was caused by 
cancer. At the same time, cancer is also an economical burden. In 2010 the 
annual economic cost of cancer was estimated to be 1.16 trillion US$ (WHO 
data: http://www.who.int/cancer/en/). But despite the obvious need and 
intensive research over the last years, cancer therapy is developing slowly. 
Classical treatments of cancer, including radiotherapy, chemotherapy and 
surgical intervention, are still considered gold-standard therapies for many 
cancers. They present however many limitations for usage including severe 
side effects due to lack of specificity and toxicity (LA-BECK et al., 2015). 
Therefore, the development of new effective treatment options has become 
a high priority in medical research, with one focus being on the 
enhancement of treatment specificity to limit negative effects on healthy 
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tissue.  
In that context, viral immunotherapy has gained considerable interest over 
the years and viral vector-based therapeutic cancer vaccines are gaining 
ground. However, despite first promising results, so far immunogenicity and 
efficacy of these vectors is still not strong enough to fully overcome the 
strong immune tolerance exhibited by tumors. Thus, research efforts to 
improve vector platforms need to be intensified to develop next generation 
vectors with increased immunogenicity and efficacy. 
 
 
 
Fig. 21: Leading causes of death worldwide in 2015. According to data 
published by the WHO in 2016: WHO methods and data sources for global 
causes of death 2000-2015. Global Health Estimates Technical Paper 
WHO/HIS/HSI/GHE/2016.3. Geneva: World Health Organization; 2016 
(http://www.who.int/healthinfo/global_burden_disease/GlobalCOD_method
_2000_2015.pdf). 
 
Reasons for choosing MVA as a vector platform  
Several different viral vectors are currently being investigated as platforms 
for the development of therapeutic cancer vaccines (LAROCCA & 
SCHLOM, 2011). One distinct feature of viral vectors is their replicative 
capacity in humans with different replicating and non-replicating vectors that 
are being developed. Undeniable, one advantage of replicating vectors such 
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as VACV is their oncolytic potential. Such oncolytic viruses are either 
naturally occurring or engineered to be tumor selective when replicating and 
therefore they are able to directly lyse infected tumor cells (KELLY & 
RUSSELL, 2007; FUKUHARA et al., 2016). But although this concept holds 
great potential in theory, concerns about the safety of replicating vectors 
have been raised. Especially immunocompromised people such as cancer 
patients are at risk of experiencing severe side effects after vaccination due 
to the incompetence of the immune system to control viral replication of the 
vector. Additionally, the vector’s toxicity, environmental shedding and the 
rates of possible mutations including the reversion to the potentially harmful 
wild type virus are being discussed (RUSSELL et al., 2012; BUIJS et al., 
2015). 
MVA is a non-replicating viral vector with a remarkable safety profile, also 
under immunocompromised conditions (STITTELAAR et al., 2001). 
Because of this, it can be safely administered to cancer patients, also as 
add-on or follow-up treatment after radio- or chemotherapy, when patients 
are known to be heavily immunocompromised. Several clinical trials to date 
have confirmed this (HARROP et al., 2013; QUOIX et al., 2016). Moreover, 
MVA is known to make stable recombinants and to be able to successfully 
deliver foreign antigens to the host cell (SUTTER & MOSS, 1992), making 
way for an efficient and strong antigen-specific immune response, an 
important feature for overcoming immune tolerance in tumors (PERKUS et 
al., 1985). Also, with more and more potential TAAs being discovered, the 
potential of delivering several antigens at the same time can be of great 
advantage (PERKUS et al., 1985). It is known that for efficacy of cancer 
vaccines, a strong T-cell response plays a crucial role. Early on it was shown 
that TAAs are recognized by both CD4+ and CD8+ T cells and that activated 
cytotoxic CD8+ T cells are able to directly lyse TAA presenting tumor cells 
(BOON et al., 1994). Moreover, spontaneous regression was observed for 
some-melanomas and was clearly associated with T cell activation and 
infiltration (LOWES et al., 1997), underlining the importance of an adequate 
T-cell response. In that context, many studies have already shown that 
recombinant MVAs are able to activate high levels of antigen-specific 
CD8+T cells (VOLZ & SUTTER, 2013; KREIJTZ et al., 2014; VOLZ et al., 
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2016) upon immunization. 
Deletion of immunomodulatory genes  
Despite the fact that the majority of immunomodulators known in VACV 
have been deleted in MVA during the attenuation process, some 
immunomodulatory genes are still conserved in MVA (MEYER et al., 1991; 
ANTOINE et al., 1998). These gene functions are responsible for 
counteracting cellular antiviral responses triggered after MVA infection. A 
number of them have been identified, studied and were shown to influence 
both, the innate as well as the acquired immune response (GARCIA-
ARRIAZA & ESTEBAN, 2014). Deleting one or more of those still intact 
genes thus provides an opportunity, to enhance MVA’s efficacy as a vector 
platform.  
The cellular induction of the apoptotic pathway is one antiviral mechanism 
MVA has to prevent after infection in order to keep the infected cell vital and 
be able to complete its life cycle. Thus, it is of no surprise that MVA encodes 
proteins with anti-apoptotic function, including the F1 protein (FISCHER et 
al., 2006). Deletion of the F1 protein in both VACV and MVA was previously 
shown to result in the induction of apoptosis in human cell lines 
(WASILENKO et al., 2005; FISCHER et al., 2006). This phenotype could be 
confirmed in this study for HeLa cells infected with MVA∆∆∆-OVA. 
Interestingly, western blot analysis of apoptosis associated caspase-3 
activation in infected cells also showed a signal for activated caspase-3 for 
MVA-OVA and MVA∆∆-OVA infected cells. However, this signal was also 
present in uninfected cells and much weaker than the signal detected in 
cells infected with MVA∆∆∆-OVA. This signal seems to be cell culture 
dependent and not specific for viral infection. At the same time, levels of 
activated caspase-3 in cells infected with MVA∆∆∆-OVA were much higher 
and comparable to levels in cells treated with Staurosporine, a known highly 
potent inducer of apoptosis and activator of Caspase-3. This is in line with 
the observation that in cells infected with MVA∆∆∆-OVA or treated with 
Staurosporine, the signal for uncleaved inactive caspase-3 vanished nearly 
completely in contrast to the strong signal detectable in cells infected with 
MVA-OVA, MVA∆∆-OVA and mock infected cells.   
Because apoptotic cell death results in a shut-down of the cell and thus of 
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the cellular machinery exploited by the virus, it could potentially be harmful 
for the viral life cycle and thus antigen production over time. However, 
deletion of the F1L ORF in VACV Copenhagen showed no signs of 
disruption of the virus life cycle (WASILENKO et al., 2005). In this study, 
multistep growth analysis also revealed no differences in replication 
capacity in primary CEF cells between MVA∆∆∆-OVA and wildtype MVA F6 
over the course of 72h despite apoptosis. At the same time, western blot 
samples obtained 15hpi from MVA∆∆∆-infected cells (MOI 5) show strong 
activation of caspase-3 and overall signs of apoptosis. However, western 
blot samples of MVA∆∆∆-OVA infected cells (MOI 5) obtained for protein 
analyses at 24hpi showed no differences in OVA production compared to 
MVA-OVA and MVA∆∆-OVA with intact F1L. Thus, the onset of apoptosis 
didn’t negatively influence antigen production in this study.  
MVA also encodes several proteins that are able to bind to and interact with 
cytokines in order to down-regulate the immune response (GARCIA-
ARRIAZA & ESTEBAN, 2014). Two of such cytokine binding proteins of 
MVA are the vIL-18bp and the vIL1βR (ALCAMI & SMITH, 1992; FALIVENE 
et al., 2012). Previous studies have confirmed that single deletion of each 
protein from the MVA genome has no negative impact on viral replication or 
antigen production (FALIVENE et al., 2012; ZIMMERLING et al., 2013). This 
was confirmed to be also true for the simultaneous deletion of both ORFs 
during this study. Neither MVA∆∆-OVA nor MVA∆∆∆-OVA showed any 
disturbance in replication capacity in primary CEF cells or antigen 
production during the course of this study.  
VACV’s vIL1βR was previously identified to be expressed late during the 
virus life cycle (ALCAMI & SMITH, 1992). This was confirmed in this study 
by ELISA analysis of supernatants from infected cells that were incubated 
with IL-1β. In supernatants collected 4hpi, comparable levels of IL1β were 
detectable in MVA-OVA and mock infected cells. However, in supernatants 
collected 8hpi and 24hpi, levels of IL-1β were significantly lower in 
supernatant from MVA-OVA infected cells compared to mock infected cells. 
This confirms expression of vIL1βR as a late protein in MVA. At the same 
time this also confirmed binding affinity of the receptor to mature IL-1β as 
described in the literature (ALCAMI & SMITH, 1992; BLANCHARD et al., 
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1998). Visually lower levels of IL-1β in supernatants from MVA-OVA 
infected cells compared to supernatants from MVA∆∆-OVA, MVA∆∆∆-OVA 
and mock infected cells were most likely due to residues of vIL1βR in the 
sucrose stock preparation of MVA-OVA. In supernatants from MVA∆∆-OVA 
and MVA∆∆∆-OVA levels of IL-1β remained equally high over time, 
confirming absence of vIL1βR. 
MVA’s vIL18bp is described as a binding protein with high affinity to mature 
IL-18 (SYMONS et al., 2002). This study confirmed the existence of a 
soluble IL-18 binding protein in the supernatant of MVA-OVA infected cells 
with the help of an ELISA. At the same, this binding protein was confirmed 
to bind mature IL-18 at high levels. IL-18 is known to stimulate IFN-γ 
production in natural killer cells (NKs) and T-cells. (BORN et al., 2000; 
READING & SMITH, 2003). In this study, we incubated supernatants of 
MVA infected cells with IL-18 in the presence of Con A and subsequently 
used them to stimulate freshly prepared murine splenocytes. Splenocytes 
stimulated with supernatant from mock infected cells that contained high 
levels of IL-18 also showed high levels of IFN- γ production, confirming IL-
18’s function as an inducer of IFN-γ in immune cells. At the same time, 
splenocytes stimulated with supernatant from MVA-OVA infected cells 
showed significantly lower levels of IFN-γ. This not only confirmed the 
existence of a functional vIL-18bp in MVA but also, that IL-18 bound to a 
binding protein is no longer biologically active.  
In vivo evaluation of immunogenicity and efficacy 
Single deletion mutants that have previously been constructed and 
described in the literature already showed promising results in terms of 
enhanced immunogenicity compared to wildtype MVA (FALIVENE et al., 
2012; PERDIGUERO et al., 2012b; ZIMMERLING et al., 2013). In this 
study, we decided to evaluate both immunogenicity and efficacy of our 
recombinant mutant MVA viruses compared to non-mutant recombinant 
MVA in vivo. Thus, we constructed all viruses to express OVA as a model 
antigen, which is a well-established concept. It is non-toxic and inert in mice, 
thus has no negative effect on the animals that could potentially influence 
results (CARROLL & FITZGERALD, 2004). To evaluate immunogenicity, 
the amount of OVA-specific CD8+ T-cells was analyzed by flow-cytometry 
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using SIINFEKL as the OVA-specific peptide to stimulate T-cells. To 
evaluate efficacy we conducted a second experiment using the EG.7 tumor 
model which is an established model system and, compared to other OVA-
expressing tumor models such as the B16, it  is considered to be less 
aggressive and thus in order opinion a good choice for a first efficacy study 
(DE TITTA et al., 2013). 
The well-established dosage most commonly used for immunization 
experiments with MVA is 1x108 PFU, with strong immune responses 
detectable (VOLZ & SUTTER, 2013). However, to have a higher chance of 
detecting differences between our constructs and MVA-OVA, we first 
decided to compare viruses with a reduced dosage of 107 PFU in our 
immunogenicity experiment. Upon prime/boost immunization of mice we 
were able to detect OVA-specific CD8+ T-cells at similar amounts in all our 
recombinant MVA viruses while mice immunized with PBS showed no OVA-
specific T-cells as expected. However, we were unable to detect significant 
differences in the amounts of OVA-specific T-cells elicited by our three 
viruses. One possible reason for that might be the dosage of 107 PFU. 
Although this is already a one log reduction compared to the most 
commonly used dosage for immunization experiments, it might still be too 
high to detect differences in immunogenicity between viruses. At the same 
time, OVA is known to be a very strong and immunodominant antigen. 107 
PFU might already be enough to saturate the system, making it unable to 
reveal differences. Against this background, we decided in order to increase 
our chances to detect differences in efficacy, to compare viruses again with 
a dosage of 107 PFU and additionally also with a lower dosage of 106 PFU. 
Nevertheless, in both dosage experiments results were very similar. We 
were able to confirm the general efficacy of MVA-based therapeutic 
vaccines in a tumor model. Regardless of the dosage, all tested viruses 
were able to significantly prolong survival while slowing down tumor growth. 
This data shows that MVA can be effective in rather low doses, an option 
that is of great advantage in the clinic, where dose reduction is of great 
importance. However, we were not able to observe any significant 
differences in efficacy between MVA-OVA and our two constructs. This 
could once again be due to the chosen dosages. Although we already 
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decided to reduce vaccine dosages compared to simple immunization 
experiments, the chosen dosages of 107 and 106 PFU might still be too high 
in order to detect differences in efficacy. This is supported by the fact, that 
both dosages more or less delivered the same results, showing that the 
amount of virus delivered with a smaller dose was still able to elicit 
comparable immune responses as the higher dose. Taken together with the 
fact that OVA was shown to be strongly expressed by MVA, the system’s 
set-up might simply not be sensitive enough to detect differences. It would 
be an option in future experiments to possibly further reduce dosages or 
look for a more sensitive model system as read-out. The studies conducted 
for the single knock-out viruses compared immunogenicity rather than 
efficacy to compare viruses and show differences. Measuring antibody and 
T-cell responses in more detail might be a more sensitive system to detect 
significant variations and could be used in further studies. Nevertheless, this 
data confirms that MVA can be effective in rather low doses, an option that 
is of great advantage in the clinic, where dose reduction is important.    
Future perspectives 
Today, safe and effective vaccine candidates on the basis of MVA are 
constantly being generated and tested for various infectious diseases. At 
the same time, more and more MVA based therapeutic cancer vaccines are 
being investigated, some of which have already entered clinical trials 
(AMATO et al., 2010; HARROP et al., 2013; QUOIX et al., 2016). However, 
until now no candidate vectors have been able to elicit strong enough 
immune responses to be highly effective, let alone curative against tumors. 
One possible approach that seems very promising is the combination of 
several therapies to maximize effect (DRAKE, 2012). Many studies have 
already combined MVA based immunotherapy with conventional first-line 
therapies (i.e. radiotherapy, chemotherapy) with promising results 
(HARROP et al., 2007; HARROP et al., 2008; AMATO et al., 2010; QUOIX 
et al., 2016). The recent successful development of other immunotherapies, 
above all the advancements made in the field of checkpoint inhibitors 
(MARTIN-LIBERAL et al., 2017), will likely make way for diverse 
combinations of different immunotherapies. For example, a recent study 
revealed that the efficacy of the checkpoint inhibitor CTLA-4 synergized with 
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an MVA-based vaccine resulting in a significantly improved median survival 
in a mouse model (FOY et al., 2016). Nonetheless, further enhancements 
of the humoral and especially the cellular immune response is certainly of 
great importance. Hence, improvements on the vector itself should be 
pursued further in order to maximize the vectors capabilities of inducing the 
strongest immune responses possible. Additionally, research on identifying 
and improving cancer specific target antigens is equally important.  
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VI. SUMMARY 
Characterization of vaccinia virus MVA candidate vaccines mutated 
in viral genes modulating inflammasome activation 
Despite ongoing intensive research efforts, cancer is still among the leading 
causes of death worldwide. In 2015 alone, an estimated 8.8 million people 
died from malignant tumors. Classical treatments (i.e. chemotherapy, 
radiotherapy and surgical treatment) are still considered to be standard of 
care for most types of cancer, although they clearly lack specificity and 
cause a variety of negative side effect in treated patients.  
Among the many approaches for novel cancer treatments, the field of viral 
immunotherapy is on the rise which uses therapeutic application of viral 
vectors to induce anti-tumoral immune responses. In that context, the live 
attenuated Modified Vaccinia virus Ankara (MVA) is being investigated as a 
potential viral vector for the construction of therapeutic cancer vaccines. It 
has already been successfully tested as a vector platform for the 
construction of prophylactic vaccines against various infectious diseases in 
several clinical studies.  MVA has an exceptionally good safety profile due 
to its replication deficiency in human cells and can thus be administered to 
risk groups with no adjuvants needed. Nevertheless, it is able to efficiently 
deliver one or more recombinant antigens and induces strong antigen-
specific humoral and cellular immune responses. However, previous studies 
have shown that MVA along with all other potential vectors is not yet able 
to elicit immune responses strong enough to fully overcome the tumor’s 
immune tolerance. 
The aim of this study was to improve MVAs potential as a viral vector by 
enhancing its immunogenicity and efficacy. Therefore, two genetically 
modified recombinant MVA viruses deficient in two (MVA∆∆-OVA) 
respectively three (MVA∆∆∆-OVA) immunomodulatory genes were 
constructed and characterized in vitro as well as in vivo using Ovalbumin 
(OVA) as a model antigen. Genetic and functional analysis showed 
successful deletion of the desired genes from the MVA genome. OVA 
expression was confirmed for all constructs at high levels. Multi-step 
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analysis of virus growth proved replication deficiency in human cells 
(HaCat), whereas replication competence was retained in primary chicken 
embryo fibroblasts (CEF) as expected. In vivo analysis of viruses was 
performed in mice with 107 PFU to compare immunogenicity and two 
different dosages (106 and 107 PFU) to compare efficacy in an E.G7 tumor 
model. Data revealed that immunization with all recombinant MVA viruses 
led to the induction of comparable amounts of OVA-specific CD8+ T-cells 
with no significant differences between viruses. Animals in the tumor model 
that received therapeutic vaccination with any recombinant MVA survived 
significantly longer and had significantly slower tumor growth than PBS 
vaccinated mice. However, no significant differences could be observed 
between any of the two constructs and MVA-OVA. Instead, significant 
differences could be observed between both construct: Upon immunization 
with 106 PFU, mice vaccinated with MVA∆∆∆-OVA showed significantly 
longer survival and slowed tumor growth at the end of the experiment. All in 
all, these data suggest that MVA has great potential as a therapeutic cancer 
vaccine and more sensitive studies should be pursued in the future to 
reinvestigate differences in efficacy and immunogenicity for such deletion 
mutants. 
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VII. ZUSAMMENFASSUNG 
Charakterisierung von MVA-Impfstoffkandidaten mutiert in 
verschiedenen viralen Genen zur Modulation der Aktivierung des 
Inflammasoms 
Trotz intensiver Forschung im Bereich der Krebstherapie gehört Krebs 
immer noch zu den häufigsten Todesursachen weltweit. Rund 8.8 Millionen 
Menschen starben allein im Jahr 2015 an bösartigen Tumorerkrankungen. 
Die drei klassischen Therapiemethoden (Chemotherapie, Strahlentherapie 
sowie die operative Tumorentfernung) gelten auch heute noch als 
Standardtherapie bei den meisten Krebsarten, obwohl sie unspezifisch und 
somit durch Schädigung von gesundem Gewebe mit vielen 
Nebenwirkungen verbunden sind.  
Nach neuen Therapieansätzen wird deshalb seit Jahren intensiv geforscht. 
Eine Strategie, die sich in den letzten Jahren als vielversprechend erwiesen 
hat, ist die virale Immuntherapie Dabei werden virale Vektorimpfstoffe 
entwickelt und eingesetzt, um spezifische anti-tumorale Immunantworten im 
Patienten hervor zu rufen. In diesem Zusammenhang wird das Modifizierte 
Vaccinia Virus Ankara (MVA) als potentieller therapeutischer Vektor 
erforscht. MVA wird bereits zur Entwicklung prophylaktischer Impfstoffen 
gegen diverse Infektionskrankheiten erfolgreich in klinischen Studien 
getestet. Es kommt ohne die Zugabe von Adjuvantien aus und eignet sich 
aufgrund seines Replikationsdefizites im Menschen auch zur Therapie 
immunsupprimierter Risikopatienten. Trotz Replikationsdefizit exprimiert 
MVA problemlos rekombinante Proteine und induziert eine antigen-
spezifische humorale und zelluläre Immunantwort. Allerdings haben 
Studien zur Nutzung viraler Vektorimpfstoffe als Krebstherapeutika gezeigt, 
dass die induzierten Immunantworten bei allen Vektoren noch nicht stark 
genug ist, um die vom Tumor induzierte Immuntoleranz vollständig zu 
durchbrechen. 
Das Ziel der vorliegenden Studie war es deshalb, MVA als Vektorimpfstoff 
hinsichtlich seiner Effizienz zu verbessern. Dafür wurden im viralen Genom 
von MVA zwei (MVA∆∆-OVA) bzw. drei (MVA∆∆∆-OVA) Gene mit 
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bekannter immunmodulatorischer Funktion deletiert und anschließend in 
vitro sowie in vivo charakterisiert. Dabei wurde Ovalbumin (OVA) als 
Modellantigen verwendet. Die zunächst durchgeführten genetischen und 
funktionellen Analysen bestätigten die erfolgreiche Deletion der 
gewünschten Gene. Die Expression von OVA wurde ebenfalls erfolgreich 
nachgewiesen. Wachstumsanalysen haben gezeigt, dass die 
rekombinanten MVA Viren weiterhin nicht fähig waren, in humanen Zellen 
zu replizieren. Die Replikationsfähigkeit in primären Hühnerzellen (CEF) 
blieb hingegen wie erwartet unverändert. Eine in vivo Evaluation erfolgte 
hinsichtlich Immunogenität in einer Impfstudie mit einer Impfdosis von 107 
PFU sowie bezüglich Effizienz im murinen EG.7 OVA Tumormodell, wobei 
zwei Impfdosen (106 und 107 PFU) vergleichsweise getestet wurden. Es 
zeigte sich, dass die Impfung mit allen rekombinanten MVA Viren zu einer 
vergleichbaren Induktion OVA-spezifischer T-Zellen führt, wobei keine 
signifikanten Unterschiede zwischen den drei Viren nachweisebar waren. In 
Mäusen, die mit einem rekombinanten MVA therapeutisch geimpft wurden, 
konnte ein signifikant verlangsamtes Tumorwachstum sowie eine signifikant 
verlängerte Überlebenszeit beobachtet werden im Vergleich zu mit PBS 
geimpften Mäusen. Jedoch konnten keine signifikanten Unterschiede 
zwischen den beiden Konstrukten und rekombinantem nicht mutiertem 
MVA nachgewiesen werden. Unterschiede hingegen konnten gezeigt 
werden zwischen den beiden Konstrukten bei einer Verabreichung von 106 
PFU, wobei das Trippelkonstrukt zu einer signifikant längeren 
Überlebenszeit führte. Insgesamt haben die Ergebnisse gezeigt, dass MVA 
großes Potential als therapeutischer Impfstoff aufweist. Weitere sensitivere 
Methoden sollten in Zukunft angewendet werden, um die 
Deletionsmutanten erneut zu testen und eventuell vorhandene 
Unterschiede besser dar zu stellen. 
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IX. APPENDIX 
1. Chemicals, reagents and consumables/plasticware 
Description Supplier 
6-/24-/96-well flat bottom plates Sarstedt, Nümbrecht, Germany 
96-well Nunc MaxiSorpTM 
microwell plates 
BioLegend, San Diego, USA 
Acetone (C3H6O) Carl-Roth GmbH, Karslruhe, 
Germany 
Acrylamide 30% (C3H5NO) AppliChem, Darmstadt, Germany 
Ammoniumpersulfate (H8N2O8S2) AppliChem, Darmstadt, Germany 
Bovine serum albumine (BSA) Sigma-Aldrich, St. Louis, USA 
Bromophenol blue Merck, Darmstadt, Germany 
Cell culture flasks (25/75/175 cm2) Sarstedt, Nümbrecht, Germany 
Color plus protein ladder New England BioLabs ® GmbH, 
Frankfurt am Main, Germany 
Color Protein Standard, broad 
range 
New England BioLabs ® GmbH, 
Frankfurt am Main, Germany 
DAPI Nucleic acid stain invitrogenTM, Carlsbad, USA 
Distilled water In-house production, LMU, 
München, Germany 
DMSO (C2H6OS) Carl-Roth GmbH, Karslruhe, 
Germany 
DTT (C4H10O2S2) Sigma-Aldrich, St. Louis, USA 
EDTA (C10H16N2O8) ICN Biochemicals, Ohio, USA 
GelRedTM Biotrend, Köln, Germany 
Glycerol (C3H8O3) Carl-Roth GmbH, Karslruhe, 
Germany 
Glycine (C2H5NO2) Carl-Roth GmbH, Karslruhe, 
Germany 
Hydrochloric acid (HCl), 6N Carl-Roth GmbH, Karslruhe, 
Germany 
Hypoxanthine Sigma-Aldrich, St. Louis, USA 
LE Agarose Biozym, Hessisch Oldendorf, 
Germany 
Methanol (CH4O) Carl-Roth GmbH, Karslruhe, 
Germany 
Monopotassium phosphate 
(KH2PO4) 
Carl-Roth GmbH, Karslruhe, 
Germany 
Mycophenolic acid (MPA) Sigma-Aldrich, St. Louis, USA 
Nitrocellulose blotting membrane, 
0.2 µm 
GE Healthcare, München, Germany 
Nonfat dried milk powder AppliChem, Darmstadt, Germany 
Paraformaldehyde Carl-Roth GmbH, Karslruhe, 
Germany 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
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Quick-Load® 2-log DNA ladder New England BioLabs ® GmbH, 
Frankfurt am Main, Germany 
Red blood cell lysing buffer Sigma-Aldrich, St. Louis, USA 
SDS (C12H25NaO4S) Carl-Roth GmbH, Karslruhe, 
Germany 
Sodium chloride (NaCl) Carl-Roth GmbH, Karslruhe, 
Germany 
Staurosporine solution from 
Streptomyces sp., 1mM 
Sigma-Aldrich, St. Louis, USA 
TEMED (C6H16N2) SigmaAldrich, St. Louis, USA 
Tris ultrapure (C4H11NO3) AppliChem, Darmstadt, Germany 
Tris-gycine buffer, 10x Bio-Rad, München, Germany 
Triton® X-100 AppliChem, Darmstadt, Germany 
TrueBlueTM Peroxidase Substrate seracare, Milford, USA 
Trypan blue  Sigma-Aldrich, St. Louis, USA 
Tween20 Sigma-Aldrich, St. Louis, USA 
Xanthine Sigma-Aldrich, St. Louis, USA 
λ DNA - Hind III and φX174 DNA - 
Hae III Mix Ready to Use Marke 
Finnzymes/Thermo Fisher Scientific, 
Walham, USA 
 
2. Laboratory equipment and software 
Equipment Supplier 
Avanti® J-26 XP Centrifuge Beckmann Coulter, Krefeld, Germany 
ChemiDocTM MP, Imaging 
System 
Bio-Rad, München, Germany 
SunriseTM  microplate 
absobance reader 
Tecan Trading AG, Männedorf, 
Switzerland 
Neubauer chamber improved Paul Marienfeld GmbH&Co.KG, Lauda-
Königshofen, Germany 
PeqSTAR 2X Thermocycler PEQLAB Biotechnology GmbH, 
Erlangen, Germany 
OptimaTM LE-80K 
Ultracentrifuge 
Beckmann Coulter, Krefeld, Germany 
Sonoplus Bandelin electronics, Berlin, Germany 
Olympus CKX41 Olympus Life Sciences, Hamburg, 
Germany 
Trans Blot Turbo system Bio-Rad, München, Germany 
KEYENCE BZ-X710 All-in-
one Fluorescence 
Microscope 
KEYENCE Deutschland GmbH, Neu-
Isenburg, Germany 
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3. Commercial kits 
Kit Supplier 
Mouse IFN-γ ELISA MAXTM Deluxe BioLegend, San Diego, USA 
Mouse IL-1β ELISA MAXTM Deluxe BioLegend, San Diego, USA 
ClarityTM ECL Western Blotting 
Substrate Bio-Rad, München, Germany 
QIAamp DNA Mini Kit Qiagen, Venlo, Netherlands 
NucleoSpin® Plasmid 
MACHERY-NAGEL 
GmbH&Co. KG, Düren, 
Germany 
NucleoSpin®  Gel and PCR Clean-up 
MACHERY-NAGEL 
GmbH&Co. KG, Düren, 
Germany 
 
4. Buffers, solutions, SDS-gels 
Buffers and 
solutions Conditions 
Loading buffer (LB), 6x 
10 mM Tris-HCl pH 7.6 
60% glycerol 
60 mM EDTA 
0.03% bromophenol blue 
add. distilled water 
Lysis buffer, 1x 
62.5 mM Tris-HCl pH 6.8 
2% SDS 
10% glycerol 
0.01% bromophenol blue 
50 mM DTT 
add. distilled water 
PBS (pH 7.4) 
140 mM NaCl 
Na2HPO4 + 7H2O 
KCl 
KH2PO4 
add. distilled water 
TAE (pH 7.8), 50x 
2 M Tris-acetate 
0.5 M NaCl 
50 mM EDTA 
add. distilled water 
TBS (pH 7.6), 10x 
200 mM Tris base 
1.4 M NaCl 
add. distilled water 
Transfer buffer, 1x 
25 mM Tris base 
200 mM glycine 
20% ethanol 
add. distilled water 
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Tris/Glycine/SDS  
(pH 8.3), 10x 
25 mM Tris 
192 mM glycine 
0.1% SDS 
 
Mycophenolic acid 
soultion 
0.25% mycophenolic acid (10mg/ml in 0.1 N 
NaOH) 
2.5%  xanthine (10mg/ml in 0.1 N NaOH) 
0.15% hypoxanthine (10mg/ml in 0.1 N NaOH) 
add. distilled water 
 
SDS-gel Conditions 
Resolving gel (10%) 
3.3 ml 30% acrylamide 
2.5 ml 1.5 M Tris-HCl, pH 8.8 
0.3 ml 10% ammonium persulfate 
0.1 ml 20% SDS 
8 µl TEMED 
add. 10 ml distilled water 
Resolving gel (15%) 
5.0 ml 30% acrylamide 
2.5 ml 1.5 M Tris-HCl, pH 8.8 
0.3 µl 10% ammonium persulfate 
0.1 ml 20% SDS 
8 µl TEMED 
add. 10 ml distilled water 
Stacking gel (5%) 
0.5 ml 30% acrylamide 
0.38 ml 1.0 M Tris-HCl, pH 6.8 
0.1 ml 10% ammonium persulfate 
60 µl 20% SDS 
6 µl TEMED 
add. 3 ml distilled water 
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